

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

17 DEC 2004

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number  
**WO 03/106505 A1**(51) International Patent Classification<sup>7</sup>: **C08B 37/00**, 37/08, 37/10, A61K 31/726, 31/727, 31/737

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/IB03/02339

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 17 June 2003 (17.06.2003)

(25) Filing Language: Italian

(26) Publication Language: English

(30) Priority Data:  
MI2002A001345 18 June 2002 (18.06.2002) IT  
MI2002A001346 18 June 2002 (18.06.2002) IT  
MI2002A001854 27 August 2002 (27.08.2002) IT**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicants and

(72) Inventors: **ORESTE, Pasqua, Anna** [IT/IT]; Via Mac Mahon, 43, I-20155 Milan (IT). **ZOPPETTI, Giorgio** [IT/IT]; Via Mac Mahon 43, I-20155 Milano (IT).(74) Agent: **SANTORO, Tiziana**; Marietti, Gislon e Trupiano S.r.l., Via Larga, 16, I-20122 Milan (IT).**WO 03/106505 A1**

(54) Title: PROCESS FOR THE MANUFACTURE OF N-ACYL-(EPI)K5-AMINE-O-SULFATE-DERIVATIVES AND PRODUCTS THUS OBTAINED

(57) Abstract: A new method is described for the oversulfation of (epi)KS-N-sulfates to obtain (epi)K5-amine-O-oversulfates at extremely high degree of sulfation and for the transformation of these intermediates into new Nacyl-(epi)K5-amine-O-oversulfates basically free of activity on the coagulation parameters and useful in the cosmetic or pharmaceutical field. Also described are pharmaceutical compositions containing, as one of their active ingredients, an (epi)K5-amine-O-oversulfate.

**Process for the manufacture of N-acyl-(epi)K5-amine-O-sulfate-derivatives and products thus obtained.**

**SUBJECT MATTER OF THE INVENTION**

The present invention concerns new derivatives of K5 polysaccharide with a high degree of sulfation, a process for their preparation, new highly O-sulfated intermediates useful in their synthesis and pharmaceutical compositions containing said derivatives of K5 polysaccharide as active ingredients basically free of activity on coagulation.

In particular, the invention refers to derivatives of K5 polysaccharide obtained starting with a K5 polysaccharide, previously N-deacetylated, N-sulfated, optionally depolymerized or optionally at least 20% C5-epimerized and optionally depolymerized, by O-versulfation in suitable conditions and subsequent N-acylation of the free amine.

**BACKGROUND OF THE INVENTION**

The glycosaminoglycans such as heparin, heparan sulfate, dermatan sulfate, chondroitin sulfate and hyaluronic acid are biopolymers extracted industrially from various animal organs.

In particular, heparin, mainly obtained by extraction from the intestinal mucous membrane of pigs or from bovine lung, is a polydispersed copolymer with a molecular weight distribution from approximately 3,000 to approximately 30,000 D consisting of a chain mixture basically consisting of a uronic acid (glucuronic acid or iduronic acid) and of an amino sugar (glucosamine) linked by bonds  $\alpha$ -1 $\rightarrow$  4 or  $\beta$ -1 $\rightarrow$  4. In heparin, the uronic unit can be O-sulfated in position 2 and the glucosamine unit is N-acetylated or N-sulfated, 6-O-sulfated and 3-O-sulfated in approximately 0.5% of the glucosamine units present.

The properties and the natural biosynthesis of heparin in mammals

have been described by Lindahl et al., 1986 in Lane, D. and Lindahl, U. (Editors) "Heparin. Chemical and Biological Properties; Clinical Applications", Edward Arnold, London, Pages 159-190, by Lindahl, U, Feingold D. S. and Rodén L, 1986 TIBS, 11, 221-225 and by Conrad H. E. "Heparin Binding Proteins", Chapter 2: Structure of Heparinoids. Academic Press, 1998. The biosynthesis of heparin occurs starting with its N-acetyl-heparosan precursor consisting of a chain mixture consisting of the repetitive glucuronyl- $\beta$ -1 $\rightarrow$ 4-N-acetylglucosamine disaccharide unit. Said precursor undergoes enzymatic modifications which partially hydrolyse the N-acetyl group, substituting it with an SO<sub>3</sub><sup>-</sup> group, epimerize the carboxy in position 5 of a part of the glucuronic units transforming them into iduronic units and introducing O-sulfate groups to get a product which, once extracted industrially, has approximately double the number of sulfate groups as regards carboxy groups per disaccharide unit. These enzymatic modifications lead, i.a. to the formation of the pentasaccharide region of a bond to antithrombin III (ATIII), called active pentasaccharide, which is the structure necessary for the high affinity bond of heparin to ATIII and fundamental for anticoagulant and antithrombotic activity of the heparin itself. This pentasaccharide, present inside only some of the chains which form heparin, contains a sulfated glucosamine unit in position 3 and a glucuronic acid spaced out between disaccharides containing iduronic acids.


In nature, the formation of the active pentasaccharide is made possible by the epimerization reaction of the carboxy of a part of the glucuronic units into iduronic units carried out by the glucuronyl-C5-epimerase (C5-epimerization) and by suitable sulfation which also leads to the introduction of a sulfate group on the hydroxyl in position 3 of the glucosamine. More particularly, in nature the formation of the

active pentasaccharide is made possible by the fact that C5-epimerization occurs in clusters, i.e. on portions of chains, and extensively which leads to a product which contains more iduronic units than glucuronic ones. In fact, commercial heparin contains approximately 70% of iduronic units and 30% of glucuronic units.

Alongside the main anticoagulant and antithrombotic activities, heparin also exercises antilipaemic, antiproliferative, antiviral, antitumorous and antimetastatic activities, but its use as a drug is hindered by the side effects due to the anticoagulant action which can cause bleeding.

#### PRIOR ART

It is known that the capsular K5 polysaccharide isolated from *Escherichia coli*, described by Vann W. F. et al., in European Journal of Biochemistry, 1981, 116, 359-364 ("Vann 1981"), is consisting of a chain mixture consisting of the repetitive disaccharide unit glucuronyl- $\beta$ -1 $\rightarrow$ 4-N-acetyl glucosamine and therefore shows the same repetitive sequence (A)



of N-acetyl-heparosan precursor of heparin. The capsular K5 polysaccharide, referred to hereafter as "K5 polysaccharide" or more simply "K5"; was chemically modified by Lormeau et al. as described in US 5,550,116 and by Casu et al. as described in Carbohydrate Research, 1994, 263, 271-284. K5-O-sulfates having antitumorous, antimetastatic, antiviral, in particular anti-HIV activities are described in EP 333243 and WO 98/34958. The K5 was also chemically and enzymatically modified in order to obtain products having in vitro

biological activity on coagulation of the same type as that of heparin as extracted from animal organs (extractive heparin).

The attainment of the products having an activity on coagulation of the same type as that of extractive heparin occurs by processes which imitate that occurring in nature and envisage the entire key step of C5-epimerization with D-glucuronyl C5 epimerase.

The processes described in IT 1230785, WO 92/17507, WO 96/14425 and WO 97/43317 utilize K5 as the starting material. The K5 originating from fermentation is subjected to N-deacetylation followed by N-sulfation and on the K5-N-sulfate thus obtained C5-epimerization with C5-epimerase in solution is performed, obtained either by chromatography of a solution of microsomal enzymes from mouse mastocytoma (IT 1230 785) or from bovine liver (WO 92/17507, WO 96/14425 and WO 97/43317).

The D-glucuronyl C5 epimerase from bovine liver was purified by Campbell, P. et al. in J. Biol. Chem., 1994, 269/43, 26953-26958 ("Campbell 1994") who also provided its composition in amino acids and described its use in solution for the transformation of a K5-N-sulfate into the corresponding 30% epimerized product, demonstrating the formation of iduronic acid by HPLC method followed by total nitrous depolymerization to disaccharide.

The document WO 98/48006 describes the DNA sequence which codes for the D-glucuronyl C5 epimerase and a recombinant D-glucuronyl C5 epimerase, obtained from a recombinant expression vector containing said DNA, afterwards purified by Campbell et al. as shown by Jin-Ping L. et al. in J. Biol. Chem. 2001, 276, 20069-20077 ("Jin-Ping 2001").

The complete sequence of the C5-epimerase was described by Crawford B. E. et al. in J. Biol. Chem., 2001, 276(24), 21538-21543

(Crawford 2001)

The document WO 01/72848 describes a method for the preparation of N-deacetylated N-sulfate derivatives of K5 polysaccharide, at least 40% epimerized of iduronic acid as regards the total of the uronic acids, having a molecular weight from 2000 to 30,000, containing from 25 to 50% of high affinity chains for ATIII and having an anticoagulant and antithrombotic activity expressed as HCII/antiXa ratio from 1.5 to 4. Said document describes the oversulfation of a 40-60% epimerized K5-N-sulfate and shows that the product obtained, whose <sup>13</sup>C-RMN is illustrated, has a sulfate group content per disaccharide unit of 2-3.5. Repeating the aforesaid oversulfation in the conditions described and examining the <sup>13</sup>C-RMN it is ascertained that the product obtained is actually a free amine whose content of 6-O-sulfate is 80-95%, that of 3-O-sulfate on the amino sugar is 30%, but whose sulfation degree is 3.2. It is also ascertained that in the conditions of oversulfation described in WO 01/72848 a sulfation degree of more than 3.2 is not obtained.

The patent application MI2001A/00397 (WO 02/068477), describes K5-N,O-versulfated having a sulfation degree of more than 3.2, obtained starting with a K5 free of lipophilic substances or one of its moieties of molecular weight of approximately 5,000 by (a) N-deacetylation/N-sulfation, (b) O-versulfation and, optionally, (c) N-resulfation.

None of the aforesaid documents describes LMW-K5-N-sulfates, optionally 40-60% epimerized, in which NH<sub>2</sub> or acetyl groups are virtually absent.

In order to standardize the terminology and render the text more comprehensible, in the present description conventional terms or expressions will be used, in the singular or plural. In particular:

- by "K5" or "K5 polysaccharide" is meant the capsular

polysaccharide from *Escherichia coli* obtained by fermentation, i.e. a chain mixture consisting of disaccharide units (A) optionally containing a double bond at the non-reducing end as shown above, in any case prepared and purified according to the methods described in literature, in particular according to Vann 1981, according to Manzoni M. et al., Journal of Bioactive Compatible Polymers, 1996, 11, 301-311 ("Manzoni 1996") or according to the method described in WO 01/72848 and in WO 02/068447; it is obvious for a person skilled in the art that what is shown hereafter can be applied to any N-acetylheparosan;

- by "C5-epimerase" is meant the D-glucuronyl C-5 epimerase, extractive or recombinant, in any case prepared, isolated and purified, in particular as described in Campbell 1994, in WO 98/48006, in Jin-Ping L. et al. in J. Biol Chem. 2001, 276, 20069-20077 (Jin-Ping 2001") or in Crawford 2001;
- by K5-amine is meant at least 95% N-deacetylated K5, but generally in which acetyl groups are undetectable by a current NMR apparatus;
- by "K5-N-sulfate" is meant at least 95% N-deacetylated and N-sulfate K5 as described hereafter, but in which acetyl groups are undetectable with a normal NMR apparatus;
- by "epiK5" is meant the K5 and its derivatives in which 20-60% of the glucuronic units are C5-epimerized to iduronic units;
- by "epiK5-N-sulfate" is meant the K5-N-sulfate in which 20-60% of the glucuronic units is C5-epimerized to iduronic units of the type described in WO 92/17507 or WO 01/72848;
- by "epiK5-amine-O-versulfate" is meant an O-sulfated epiK5-amine with a sulfation degree of at least 3.4;
- by "N-acyl-epiK5-amine-O-versulfate" is meant an N-acylated epiK5-amine O-versulfate, with a sulfation degree of at least 3.4;

- by "K5-amine-O-versulfate" is meant an O-sulfated K5-amine with a sulfation degree of at least 2.2;
- by "N-acyl-K5-amine-O-versulfate" is meant an N-acylated N-acyl-K5-amine-O-versulfate with a sulfation degree of at least 2.2;

In addition:

- the conventional terms and expressions herein defined above refer to K5 as isolated after fermentation, generally with a molecular weight distribution from approximately 1,500 to approximately 50,000 with a mean molecular weight of 10,000- 25,000, advantageously of 15,000-25,000;
- excepting specific designation of the molecular weight, the conventional terms and expressions herein defined above, when preceded by the acronym "LMW" (low molecular weight), for example LMW-K5-N-sulfate, LMW-epiK5-N-sulfate indicate low molecular weight products, having a mean molecular weight of up to 12,000;
- the conventional terms and expressions as herein defined above, when followed by "-derivative" indicate as a whole both the derivatives from native K5 and those of a low molecular weight;
- the prefix "(epi)", which precedes "K5" in conventional terms and expressions as herein defined above, indicates as a whole both the products from native K5 and those 20-60% epimerized as defined above, i.e. chain mixtures all consisting ofglucuronic acid or glucuronic acid and, 20-60%, of iduronic acid and is denoted in the formulae by the symbol " $\ddagger$ ";
- by the term "approximately" referring to the molecular weight is meant the molecular weight [ $\pm$  the theoretical weight of a disaccharide unit, including the weight of the sodium, calculated as 461 in the case of an (epi)K5-N-sulfate-derivative] measured by

viscometry according to Johnson et al. Carb. Res. 1976, 51, 119-127 utilizing samples whose molecular weight was calculated by HPLC as the standard;

- by the expression "preponderant species", is meant the compound which, in the mixture constituting a Imw-(epi)K5-N-sulfate, a Imw-(epi)K5-amine-oversulfate or a Imw-N-acyl-(epi)K5-amine-O-oversulfate, is the most represented type, determined by the peak of the curve of the molecular weight measured by HPLC;
- unless otherwise specifically stated, by "degree of sulfation" is meant the  $\text{SO}_3^-/\text{COO}^-$  ratio, expressible also as the number of sulfate groups per disaccharide unit, measured with the conductometric method described by Casu B. et al. in Carbohydrate Research, 1975, 39, 168-176 (Casu 1975), the same utilized in WO 01/72848;
- by "conditions of O-oversulfation" is meant an extreme O-sulfation performed for example according to the method C described by B. Casu et al. in Carbohydrate Research, 1994, 263, 271-284 (Casu 1994);
- by the term "alkyl" is meant a linear or branched alkyl, whereas the term "tetrabutylammonium" indicates the tetra-n-butylammonium.

#### SUMMARY OF THE INVENTION

It has now been found that, starting with an epiK5-N-sulfate, it is possible to obtain an epiK5-amine-O-sulfate with a degree of sulfation greater than that of every other epiK5-amine-O-sulfate described in literature, for example in WO 01/72848, preparing the salt with a tertiary or quaternary organic base of said epiK5-N-sulfate-derivative taking care to let the reaction mixture to stand for a time period of 30-60 minutes maintaining the pH at approximately 7 with the same organic base and then treating the salt obtained with an O-sulfation reagent in the conditions of O-oversulfation. Also a Imw-epiK5-N-sulfate, when subjected to the same method of salification and of O-

oversulfation, gives a Imw-epiK5-amine-O-sulfate with an extremely high degree of sulfation. In the case of such epi-K5-amine-oversulfate-derivatives the degree of sulfation is more than 3.2.

Similarly, it was found that, applying the conditions of O-versulfation described above to a Imw-K5-N-sulfate a Imw-K5-amine-O-sulfate is obtained at a high degree of sulfation. Also a K5-N-sulfate, when subjected to the same method of salification and of O-versulfation, gives a K5-amine-O-sulfate with a high degree of sulfation. In the case of such K5-amine-oversulfate-derivatives the degree of sulfation is more than 2.2.

In fact, it was surprisingly found that, preparing the tetrabutylammonium salt of an (epi)K5-N-sulfate-derivative in the aforesaid conditions, the salification becomes complete and, during the subsequent O-versulfation, favours the total displacement of the sulfate group from the nitrogen atom in position 2 of the glucosamine to the oxygen atoms of the glucosamine itself, in particular to the oxygen atom in position 3, thus giving rise to (epi)K5-amine-O-sulfate-derivatives with a high degree of sulfation in which the NH<sub>2</sub> group is strictly free. The quantitative difference in sulfation degree of the derivatives epiK5 and K5 depends on their configuration which favours the sulfation of the epimerized derivatives.

It has also been found that, subjecting an (epi)K5-amine-O-versulfate-derivative thus obtained to N-acylation, new N-acyl-(epi)K5-amine-O-sulfate-derivatives are obtained free of activity on coagulation and useful for the preparation of pharmaceutical or cosmetic compositions. By this new and versatile process it is thus possible to prepare in a reproducible manner epiK5-O-sulfate-derivatives, their N-acyl analogues, a K5-O-sulfate having a precise degree of sulfation and, above all, its derivatives of low molecular

weight and their N-acyl-analogues.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the NMR proton spectrum of K5-NH<sub>2</sub> O-sulfate with a sulfate/carboxy ratio of 2.87 (obtained according to Example 1);

Figure 2 shows the NMR proton spectrum of epiK5-N-acetylate, O-sulfate with a sulfate/carboxy ratio of 4.26 (obtained according to Example 2);

Figure 3 shows the NMR proton spectrum of K5-N-acetylate, O-sulfate with a sulfate/carboxy ratio of 2.87 (obtained according to Example 3).

#### DETAILED DESCRIPTION

Thus, according to one of its aspects, the present invention provides a process for the preparation of N-acyl-(epi)K5-amine-O-versulfate-derivatives, characterized in that

- (a) an (epi)K5-N-sulfate-derivative, in acidic form, is treated with a tertiary or quaternary organic base, letting the reaction mixture to stand for a time period of 30-60 minutes, maintaining the pH of the solution at a value of approximately 7 and its salt is isolated with said organic base;
- (b) said salt of organic base of said (epi)K5-N-sulfate-derivative is treated with an O-sulfation reagent in the conditions of O-versulfation;
- (c) the product thus obtained is treated with a functional derivative of a (C<sub>2</sub>-C<sub>4</sub>) carboxylic acid, the N-acyl-(epi)K5-amine-O-versulfate-derivative thus obtained is isolated.

Generally the N-acyl-(epi)K5-amine-O-versulfate-derivative is isolated in sodium salt form and optionally said sodium salt is transformed into another chemically or pharmaceutically acceptable salt.

In this context, the term "chemically acceptable" refers to a cation

usable in chemical synthesis, such as the ions sodium, ammonium, (C<sub>1</sub>-C<sub>4</sub>)tetraalkylammonium, or for the purification of the product, whereas "pharmaceutically acceptable" is self-explanatory.

Advantageous cations are those derived from alkaline metals, alkaline-earth metals, ammonium, (C<sub>1</sub>-C<sub>4</sub>)tetraalkylammonium, aluminum and zinc. Preferred cations are the sodium, calcium and tetrabutylammonium ions.

According to an advantageous procedure, the step (a) is carried out by passing a solution of the sodium salt of the(epi)K5-N-sulfate-derivative, i.e. of K5 polysaccharide, previously N-deacetylated, N-sulfated preferably 100%, optionally 20-60% C5-epimerized and optionally depolymerized with nitrous acid, having a mean molecular weight from approximately 1,000 to approximately 25,000, advantageously from approximately 1,500 to approximately 25,000, through an acid ionic exchange resin, for example of the type IR-120 H<sup>+</sup>, collecting the eluate including also the washing water of the resin and neutralizing the eluate with tertiary or quaternary organic base, preferably with an aqueous solution of tetrabutylammonium hydroxide. The solution is let to stand for 1 hour, maintaining its pH at approximately 7 (i.e. trying to maintain neutrality) by addition of the same tertiary or quaternary organic base, preferably an aqueous solution of tetrabutylammonium hydroxide, and the salt thus obtained is recovered by lyophilization.

In step (b), the O-versulfation occurs utilizing an excess of O-sulfating agent and working at a temperature from 20 to 70°C for a time period of up to 24 hours in an aprotic polar solvent.

Advantageously, the salt with a tertiary or quaternary organic base of the(epi)K5-N-sulfate-derivative, i.e. of K5 polysaccharide, previously N-deacetylated, N-sulfated preferably 100%, optionally 20-60% C5-

epimerized and optionally depolymerized with nitrous acid, having a mean molecular weight from approximately 1,500 to approximately 25,000 as isolated in step (a), is dissolved in dimethylformamide and treated with 2 – 10 moles of an O-sulfation reagent for every free hydroxyl at a temperature of 40-60°C for 10-20 hours. As the O-sulfation reagent is advantageously used the pyridine.SO<sub>3</sub> adduct in a quantity of 2.5 – 5 moles, preferably 2.5 – 4 moles per free hydroxyl per disaccharide and the reaction is advantageously carried out at 50-60°C, preferably at 55°C overnight. The product obtained upon termination of the reaction is isolated by the addition of 0.1-1 volume of water and neutralization, preferably with sodium hydroxide, precipitation with a saturated sodium chloride solution in acetone, filtration and possible ultrafiltration.

The product thus obtained is generally the sodium salt of an (epi)K5-amine-O-versulfate-derivative having a glucuronic and iduronic acids content as shown above. When the oversulfation reaction is performed on the salt of the tertiary or quaternary base, preferably on the tetrabutylammonium salt of an epiK5-N-sulfate-derivative having a mean molecular weight from approximately 1,000 to approximately 25,000, advantageously from approximately 1,500 to approximately 25,000 in which the iduronic acid is 20-60% of the total of the uronic acids, an epiK5-amine-O-versulfate-derivative is obtained having a mean molecular weight from approximately 3,500 to approximately 40,000, advantageously from approximately 4,500 to approximately 40,000, and a sulfation degree of at least 3.4, advantageously of at least 3.5, more advantageously from 3.55 to 4, preferably from 3.55 to 3.8.

When the oversulfation reaction is performed on the salt of the tertiary or quaternary base, preferably on the tetrabutylammonium salt of a

K5-N-sulfate-derivative having a mean molecular weight from approximately 1,500 to approximately 25,000, a K5-amine-O-versulfate-derivative is obtained having a mean molecular weight from approximately 3,500 to 40,000, advantageously from approximately 4,500 to approximately 40,000 and a sulfation degree of at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9. Preferably, the product thus obtained comes from a Imw-K5-N-sulfate and is preferably the sodium salt of a Imw-K5-amine-O-versulfated having a degree of sulfation from 2.3 to 3. The mean molecular weight of such product can be from approximately 3,500 to approximately 11,000.

The sodium salt thus obtained can be converted into another salt. By way of example, calcium ionic exchange can be performed working with an ultrafiltration membrane.

In step (c), the (epi)K5-amine-O-versulfate-derivative with a high degree of sulfation is N-acylated utilizing the known methods in literature.

The N-acylation is performed by making the (epi)K5-amine-O-versulfate-derivative originating from step (b) react with a functional derivative of a mono or dicarboxylic acid containing from 2 to 4 carbon atoms in hydroalcoholic solution at a temperature of approximately 4°C. As functional derivatives of said (C<sub>2</sub>-C<sub>4</sub>) carboxylic acids, preferably of acetic, propionic, malonic, or succinic acid or of mono esters, in particular methylic or ethylic, of the latter, one can use the anhydride, the chloride, a mixed anhydride or an active ester. The product obtained, an N-(C<sub>2</sub>-C<sub>4</sub>)acyl-(epi)K5-amine-O-versulfate-derivative, is neutralized with a base, preferably sodium hydroxide, and then isolated by ultrafiltration and precipitation with a saturated sodium chloride solution in acetone. Optionally the step of N-acylation

is repeated until obtaining total substitution or however more than 95%. Are thus obtained the N-acyl-(epi)K5-amine-O-versulfates, in particular the N-acetyl-, N-(2-carboxy)acetyl-, N-(2-methoxycarbonyl)acetyl-, N-(2-ethoxycarbonyl)acetyl-, N-propionyl-, N-(3-carboxy)propionyl-, N-(3-methoxycarbonyl)propionyl-, N-(3-ethoxycarbonyl)propionyl-(epi)K5-amine-O-versulfates.

The new N-acyl-(epi)K5-amine-O-versulfate-derivatives thus obtained are generally in their sodium salt forms. Said sodium salt can be converted into another chemically or pharmaceutically acceptable salt. Particularly advantageous salts are those of alkaline metals, alkaline-earth metals, of ammonium, (C<sub>1</sub>-C<sub>4</sub>)tetraalkylammonium, aluminum and zinc. The salts of sodium, calcium and tetrabutylammonium are preferred.

Unlike the process described in WO 98/34958, which consists in a sulfation in heterogeneous phase of the K5 sodium salt to obtain K5-O-sulfates (according to the terminology used herein "N-acetyl-K5-amine-O-sulfates") with a degree of sulfation from 0.5 to 4 and which has to resort to the use of chlorosulfonic acid to obtain derivatives of low molecular weight in an uncontrolled manner, the process of the present invention is extremely versatile. In fact, it allows the preparation of N-acyl-K5-amine-O-versulfates of every type in very high yields, with easily controllable reactions. In particular, the process of the present invention allows the preparation of N-acyl-K5-amine-O-versulfates otherwise unobtainable, like the epimerized C-5 derivatives, the N-acylated derivatives with a different acyl from the acetyl present in the native K5 and the derivatives of low molecular weight. Besides, unlike the method described in WO 98/34958, the process of the present invention allows the attainment of LMW-K5-O-sulfates in controlled manner in order to obtain the mean molecular

weight desired and, above all, a well defined sulfation degree which can range from 2.3 to 3 but which can regularly be 2.7-2.9. Finally, all the products of the process of the present invention, in particular the free intermediate amines and the N-acyl-K5-amine-O-versulfates are useful active ingredients for pharmaceutical or cosmetic compositions.

The starting materials of step (a) are (epi)K5-N-sulfate-derivatives known in literature or their moieties, or LMW-(epi)K5-N-sulfates prepared by nitrous depolymerization of the corresponding (epi)K5-sulfates.

The starting (epi)K5-N-sulfate-derivatives have a mean molecular weight from approximately 1,000 to approximately 25,000, advantageously from approximately 1,500 to approximately 25,000. Preferably, as starting material is used an (epi)K5-N-sulfate having a mean molecular weight between 10,000 and 25,000 or LMW-(epi)K5-N-sulfate having a mean molecular weight from approximately 1,500 to approximately 12,000, advantageously from approximately 1,500 to approximately 8,000, preferably from approximately 1,500 and approximately 7,500.

A ImwepiK5-N-sulfate having an iduronic units content of approximately 20%, obtained by N-deacetylation, N-sulfation and C5-epimerization of a moiety of K5 having a mean molecular weight of 5,000 is described in WO 92/17507, but this product contains a high percentage of acetyl groups.

An epiK5-N-sulfate particularly advantageous as starting material is that obtained by epimerization of a K5-N-sulfate virtually free of acetyl groups in turn prepared from particularly pure K5, in particular not containing lipophilic substances, described in WO 02/068477.

The low molecular weight C5-epimerized K5-N-sulfates having a higher

content of iduronic units, in particular 40-60%, preferably 50-55%, are instead particularly advantageous new products as starting materials in the preparation of the N-substituted epiK5-amine-O-versulfated-derivatives of the present invention.

The LMW-epiK5-N-sulfates can also be obtained by C5-epimerization of the corresponding LMW-K5-N-sulfates, preferably when their mean molecular weight is more than 4,000. The LMW-K5-N-sulfates virtually free of acetyl groups are all new products preparable by fractionation or, preferably, by depolymerization of a K5-N-sulfate free of acetyl groups. The K5-N-sulfate is well known in literature and is described in documents cited herein above to illustrate the state of the art. The aforesaid starting material is invariably obtained by N-deacetylation of K5 and subsequent N-sulfation of the K5-amine thus obtained. However, it was ascertained that the preparation of a K5-N-sulfate virtually free of acetyl or NH<sub>2</sub> groups is helped if the K5 from which it is prepared is particularly pure, in particular if it does not contain lipophilic substances. It is therefore preferred, according to the present invention, to use a starting K5-N-sulfate prepared from a purified K5 as described in WO 02/068477. Said K5-N-sulfate, whose <sup>13</sup>C-RMN spectrum does not show traces of N-acetyl or NH<sub>2</sub> groups is also described in WO 02/068477.

The new LMW-epiK5-N-sulfates as shown above are prepared by a process characterized in that a K5-N-sulfate is subjected, in any one order,

- (i) to C5-epimerization with a D-glucuronyl C5-epimerase that is isolated, purified and in solution or immobilized on a solid support, at a pH of approximately 7, at a temperature of approximately 30°C and for a time period of 12-24 hours in the presence of at least one bivalent ion selected among calcium, magnesium, barium and manganese; and

(ii) to nitrous depolymerization optionally followed by reduction, normally with sodium borohydride.

The expression "in any order" shows that the process can be indifferently carried out both in the direction (i)-(ii), i.e. in the sequence above indicated, and in the reverse direction, i.e. also in the direction (ii)-(i), subjecting the K5-N-sulfate at first to the nitrous depolymerization reaction, optionally followed by reduction with sodium borohydride, and afterwards to the C5-epimerization in the aforesaid conditions. The preferred order is in the direction (i)→(ii). The sequence (ii)-(i) is preferably utilized starting with LMW-K5-N-sulfates having a mean molecular weight of more than 4000, preferably starting with approximately 6,000. For example, one can determine the amounts of sodium nitrite which, starting with 1 g of epiK5-N-sulfate, allow the attainment of a Imw-epiK5-N-sulfate with a molecular weight of more than 4,000, in particular of at least 6,000, so as to obtain useful intermediates for the preparation of LMWeipiK5-N,O-versulfates. In fact, in this case, in step (ii) the percentage of optimum epimerization is obtained.

According to a preferential aspect of the invention, the C5-epimerase is immobilized on an inert solid support.

The C5-epimerase, preferably recombinant, isolated and purified for example according to Campbell 1994, WO 98/48006, Jin-Ping 2001 or Crawford 2001, is immobilized on an inert support in the presence of the substrate, i.e. in the presence of starting K5-N-sulfate-derivative or in the presence of LMW-K5-N-sulfate, advantageously having a mean molecular weight of more than 4,000, preferably of at least 6,000. The immobilization is performed according to conventional methods, for example as described in WO 01/72848.

The C-5epimerization reaction is carried out by recirculating 20-1,000

ml of a solution of 25 mM HEPES at a pH of approximately 7 containing 0.001-10 g of substrate (K5-N-sulfate or LMW-K5-N-sulfate, preferably with a molecular weight of more than 4,000, in particular of at least 6,000) and a cation selected among calcium, magnesium, barium and manganese at a concentration between 10 and 60 mM through a column containing from  $1.2 \times 10^7$  to  $3 \times 10^{11}$  cpm of the immobilized enzyme, maintaining the pH at approximately 7 at approximately 30°C, at a flow of 30-220 ml/hour for a time period of 12-24 hours, advantageously of 15-24 hours.

Preferably the said solution is recirculated at a flow of approximately 200 ml/hour overnight (15-20 hours). The product obtained is purified and separated according to known methods, for example by ultrafiltration and precipitation with ethanol. The product thus obtained is comprised either of epiK5-N-sulfate (and in such case is dissolved in water and subjected to depolymerization) or of LMW-epiK5-N-sulfate (in such case it constitutes the end product). The percentage of epimerization, in practice the amount of iduronic units as regards the glucuronic ones, is calculated with  $^1\text{H-RMN}$  according to the method described in WO 96/4425.

The nitrous depolymerization reaction is carried out according to known methods by the depolymerization of heparin, for example according to the method described in EP 37319, in WO 82/03627 or according to the method by depolymerization of a K5-N-sulfate described in EP 544592, but starting with a K5-N-sulfate or an epiK5-N-sulfate containing from 0 to no more than 10%, preferably no more than 5%, of acetyl groups. Preferably, the depolymerization, performed with sodium nitrite and hydrochloric acid on an epiK5-N-sulfate virtually free of acetyl groups, is followed by *in situ* reduction with sodium borohydride.

In practice, a cold aqueous solution of epiK5-N-sulfate is brought to acid pH (approximately 2) with hydrochloric acid and, still cold, treated with sodium nitrite maintaining the temperature (approximately 4°C) and the pH (approximately 2) constant and, upon termination of depolymerization (approximately 15 - 30 minutes) the solution is neutralized with sodium hydroxide and treated, still at approximately 4°C, with an aqueous solution of sodium borohydride. Upon termination of the reduction (approximately 4 hours) the excess sodium borohydride is destroyed with hydrochloric acid, the solution is neutralized with sodium hydroxide and the depolymerized (and reduced) product is isolated according to known methods, for example by straightforward precipitation with ethanol or acetone. The product obtained upon termination of the depolymerization can be either a Imw-epiK5-N-sulfate (in such case it constitutes the end product) or a Imw-K5-N-sulfate (and in such case is directly subjected to C5-epimerization as shown herein above, after isolation or also in solution without being previously isolated), in particular when it has a mean molecular weight of more than 4,000, preferably of at least 6,000, or is utilized to prepare LMW-K5-N,O-versulfated of antiangiogenetic and antiviral activity. By appropriately controlling the depolymerization reaction, in particular utilizing different amounts of sodium nitrite/hydrochloric acid, LMW-K5-N-sulfates or LMW-epiK5-N-sulfates are obtained having a mean molecular weight in the entire interval from approximately 1,500 to approximately 12,000, advantageously from approximately 1,500 to approximately 10,000, preferably from approximately 1,500 to approximately 7,500, calculated at the  $^{13}\text{C}$ -RMN spectrum through the integration of the signal attributed to the C2 of the 2,5-anhydromannitol with that of the anomeric carbon of the glucosamine inside the polysaccharide chain.


According to a general procedure starting for example with 1 g of K5-N-sulfate or of epiK5-N-sulfate, the starting product is dissolved in 100-200 ml of deionized water and thermostated at 4 °C. Then an amount of sodium nitrite is added so as to obtain the mean molecular weight desired, for example from approximately 2,000 to approximately 4,000. Therefore, starting with an epiK5-N-sulfate having a molecular weight of 20,000 measured with HPLC method equipped with a BioRad BioSil 250 column and utilizing a heparin standard of known molecular weight, will require the addition of from 330 to 480 mg of sodium nitrite dissolved in a 0.2% aqueous solution. The solution containing the epiK5-N-sulfate and the sodium nitrite, kept at 4°C, is brought to pH 2 through addition of 0.1 N HCl cooled to 4°C. It is reacted under slow agitation for 20-40 minutes, then is neutralized with 0.1 N NaOH. The product obtained is brought to room temperature and treated with reducing agent such as for example sodium borohydride (250-500 mg dissolved in 50-100 ml of water) and reacted for 4-8 hours. The excess sodium borohydride is eliminated bringing the pH to 5-5.5 with 0.1 N HCl and let to stand for a further 2-4 hours. In the end it is neutralized with 0.1 N NaOH and the product is recovered by precipitation with acetone or ethanol after having concentrated the product through evaporation at reduced pressure.

Similarly, the amounts of sodium nitrite can be determined which, starting with 1 g of K5-N-sulfate or of epiK5-N-sulfate, allow the attainment of a lmw-K5-N-sulfate or a lmw-epiK5-N-sulfate with a mean molecular weight from approximately 4,000 to approximately 12,000, advantageously from approximately 4,000 to approximately 7,500, in particular of 6,000-7,500.

The LMW-epiK5-N-sulfates thus obtained, with an iduronic acid content from 20 to 60%, advantageously from 40 to 60%, preferably of 50-55%

and virtually free of NH<sub>2</sub> and N-acetyl groups, having a mean molecular weight from approximately 1,500 to approximately 12,000, advantageously from approximately 1,500 to approximately 10,000, preferably from approximately 1,500 to approximately 7,500 and their chemically or pharmaceutically acceptable salts constitute new products useful as starting materials in the preparation of particularly interesting LMW- epiK5-N,O-versulfates, but also themselves useful as active ingredients of pharmaceutical or cosmetic compositions and constitute an additional aspect of the present invention.

Advantageously, the starting materials in the preparation of the N-acyl-(epi)K5-amine-O-versulfate-derivatives of the present invention are (epi)K5-N-sulfate-derivatives consisting of a chain mixture in which at least 90% of said chains have the formula I



in which the glucuronic units/iduronic units ratio is from 100/0 to 40/60, n is an integer from 2 to 100, advantageously from 3 to 100, and the corresponding cation is chemically or pharmaceutically acceptable. In particular, said starting (epi)K5-N-sulfate-derivatives are consisting of a chain mixture in which at least 90% of said chains have the aforesaid formula I, with a glucuronic units content from 100 to 40%, advantageously with a glucuronic acid content of 100% or 80-40% of glucuronic acid and 20-60% of iduronic acid, n is an integer from 2 to 100, advantageously from 3 to 100 and the corresponding cation is chemically acceptable. Preferably, the glucuronic acid content is 100% or out of the total of uronic acids 40-60% is glucuronic acid and


60-40% is iduronic acid.

Preferred starting materials are LMW-(epi)K5-N-sulfates consisting of a chain mixture in which at least 90% of said chains have the formula I in which the uronic units are all consisting of glucuronic acid or are 40-60% comprised, preferably 50-55%, of iduronic acid, n is a integer from 2 to 20, advantageously from 3 to 15 and the corresponding cation is chemically acceptable. The epiK5-N-sulfates, prepared by C5-epimerization of K5-N-sulfates, are well known and widely described in literature. Their preparation by C-5 epimerization of the glucuronic unit of K5-N-sulfate with a D-glucuronyl C5 epimerase was described in documents cited herein above to illustrate the state of the art, for example in WO 92/17507, WO 98/14425, WO 97/43317, WO 01/72848 and US 2002/0062019. However, according to a preferential manner of procedure, by epimerization a K5-N-sulfate is used obtained from a K5 free of lipophilic substances as described in WO 02/068477 and the C5 epimerization is performed with a D-glucuronyl C5-epimerase isolated, purified and immobilized on a solid support, at a pH of approximately 7, at a temperature of approximately 30°C and for a time period of 12-24 hours in the presence of at least one bivalent ion selected among calcium, magnesium, barium and manganese as shown above. Also the K5-N-sulfate was shown herein above.

The completely N-sulfated (epi)K5-N-sulfates of low molecular weight, in particular those in which the uronic units are all in glucuronic acid and those having an iduronic units content of 40-60%, preferably 50-55%, are instead all particularly advantageous new products as starting materials in the preparation of the N-acyl-(epi)K5-amine-O-versulfate-derivatives according to the present invention. Said starting materials are LMW-(epi)K5-N-sulfates having an iduronic acid content of 0% or 40-60% as regards the total of the uronic acids and a

mean molecular weight from approximately 1,500 to approximately 12,000, advantageously from approximately 1,500 to approximately 8,000, preferably from approximately 1,500 to approximately 7,500; and their chemically or pharmaceutically acceptable salts. The distribution can range from approximately 1,000 to approximately 10,000.

Said LMW-(epi)K5-N-sulfates are advantageously consisting of a chain mixture in which at least 90% of said chains have the formula I'




in which the uronic units are 100% consisting of glucuronic acid or 60-40% of glucuronic acid and 40-60% of iduronic acid, q is an integer from 2 to 20 and the corresponding cation is chemically or pharmaceutically acceptable.

In this context, the term "chemically" refers to a cation usable in chemical synthesis, such as the ions sodium, ammonium, (C<sub>1</sub>-C<sub>4</sub>)tetraalkylammonium, or for the purification of the product.

Advantageous cations are those derived from alkaline metals, alkaline-earth metals, ammonium, (C<sub>1</sub>-C<sub>4</sub>)tetraalkylammonium, aluminum and zinc. Preferred cations are the sodium, calcium and tetrabutylammonium ions.


Preferred starting materials are the new LMW-(epi)K5-N-sulfates consisting of a chain mixture in which the preponderant species has the formula I'a




in which the uronic units are 100% consisting of glucuronic acid or 60-40% glucuronic and 40% to 60% of iduronic acid, p is an integer from 4 to 8. The mean molecular weight of these products is from approximately 2000 to approximately 4000 and the corresponding cation is chemically or pharmaceutically acceptable.

In particular the new LMW-(epi)K5-N-sulfates are useful starting materials consisting of a chain mixture in which at least 90% of said chains have the formula I' herein above, obtained by nitrous depolymerization of the corresponding (epi)K5-N-sulfates shown above and subsequent possible reduction for example with sodium borohydride.

The origin of these (epi)K5-N-sulfates from a step of nitrous depolymerization involves, at the reducing end of the majority of the chains in said chain mixture, the presence of a 2,5-anhydromannose unit or, in case of reduction with for example sodiumborohydride, of 2,5-anhydromannitol of structure (a)




in which X represents a formyl group or a hydroxymethyl group. Therefore, the reducing end of the majority (60-70%) of the chains is actually represented by the structure (b)



in which X is as defined above.

The presence of the structure (a) does not have any influence on the chemical characteristics of the (epi)K5-N-sulfates and their derivatives since any sulfations would involve a possible introduction of one or two sulfate groups which would not significantly change however the sulfation degree of the O-sulfated derivatives. Besides, the presence of the structure (a) does not influence biological activity of the products, as demonstrated by Østergaard P. B. et al. in Thrombosis Research, 1987, 45, 739-749 (Østergaard 1987) for heparins of low molecular weight.

Particularly advantageous LMW-(epi)K5-N-sulfates according to the present invention are consisting of chain mixtures in which the preponderant species is a compound of formula I'b



in which X is formyl or hydroxymethyl, m is 4, 5 or 6, the corresponding cation is one chemically or pharmaceutically acceptable ion, the uronic units are all of glucuronic acid or the glucuronic and iduronic units are present alternately, starting with a glucuronic or iduronic unit. In such case the Glucuronic/iduronic ratio is from 45/55 to 55/45, i.e. approximately 50/50.

All the LMW-(epi)K5-N-sulfates herein shown above are new products which constitute an additional object of the present invention.

The LMW-(epi)K5-N-sulfates, i.e. the LMW-K5-N-sulfates shown above and, unlike other epiK5-N-sulfates, for example as indicated in WO 92/17507, also the LMW-epiK5-N-sulfates of the present invention, being virtually free of N-acetyl groups, do not have anticoagulant activity and have an interesting activity against the free radicals. Thanks to their low toxicity, the new LMW-K5-N-sulfates and LMW-epiK5-N-sulfates are active ingredients for the preparation of pharmaceutical compositions utilizable as adjuvants in the treatment of ischemic cardiopathy and for the treatment of radiation dermatitis or of cosmetic compositions useful as anti-ageing of the skin.

When the LMW-(epi)K5-N-sulfates shown above are used as starting materials for the O-versulfation reaction, it is in any case preferred that, in their preparation by nitrous depolymerization as shown above, said depolymerization is followed by the reduction for example with sodium borohydride to give LMW-K5-N-sulfates characterized by terminal units (a) in which X is hydroxymethyl, since according to the process of the present invention said LMW-(epi)K5-N-sulfates are subjected to reactions of sulfation and acylation whose influence, of the 2,5-anhydromannose radical of structure (a) is unknown on the formyl group, in which X represents formyl.

Said starting materials are preferably used in sodium salt form, unless a salt is already available with a tertiary or quaternary organic base prepared according to step (a) shown above, preferably the tetrabutylammonium salt.

According to the present invention, the starting (epi)-K5-N-sulfate-derivatives, preferably 100% N-sulfated, are subjected to the aforesaid steps (a) and (b), upon termination of which are isolated the corresponding, new (epi)K5-amine-O-versulfate-derivatives, in which the amine is not substituted, normally in sodium salt form, which can

be transformed into another chemically or pharmaceutically acceptable salt.

Thus, according to another of its aspects, the present invention refers to new (epi)K5-amine-O-versulfate-derivatives and their chemically or pharmaceutically acceptable salts, obtainable by a process characterized in that

- (a) an (epi)K5-N-sulfate-derivative, in acidic form, is treated with a tertiary or quaternary organic base, letting the reaction mixture to stand for a time period of 30-60 minutes, maintaining the pH of the solution at a value of approximately 7 by addition of said tertiary or quaternary organic base and its salt is isolated with said organic base;
- (b) said salt of organic base of said (epi)K5-N-sulfate-derivative is treated with an O-sulfation reagent in the conditions of O-versulfation and the (epi)K5-amine-O-versulfate-derivative is isolated.

The derivative thus obtained is generally an (epi)K5-amine-O-versulfate-derivative having a mean molecular weight from approximately 4,500 to approximately 40,000, isolated in sodium salt form which can be transformed into another chemically or pharmaceutically acceptable salt. Particularly advantageous salts are those of alkaline metals, alkaline-earth metals, of ammonium, (C<sub>1</sub>-C<sub>4</sub>)tetraalkylammonium, aluminum and zinc and, among these, the salts of sodium, calcium and tetrabutylammonium are preferred.

As already herein shown above, the degree of sulfation of the (epi)K5-amine-O-versulfate-derivatives as obtained above depends on the configuration of the starting (epi)K5-N-sulfate-derivative, since the volume in the disaccharide chain of K5-N-sulfate-derivative, in which the uronic units are comprised exclusively of glucuronic acid, allows a oversulfation which is less than that occurring with the epiK5-N-sulfate-derivative, especially if the epimerization degree of the latter is 40-60%


of glucuronic acid and 60-40% of iduronic acid.

In fact it has been ascertained that, subjecting a K5-N-sulfate-derivative to the aforesaid steps (a) and (b) a K5-amine-O-versulfate-derivative is obtained having a sulfation degree from 2.2 to 3, advantageously from 2.5 to 3, preferably from 2.7 to 2.9.

Subjecting an epiK5-N-sulfate-derivative to the aforesaid steps (a) and (b) in which the iduronic acid content is 20-60%, preferably 40-60% of the total of the uronic acids, an epiK5-amine-O-versulfate-derivative is obtained having a sulfation degree of at least 3.4, advantageously of at least 3.5, more advantageously from 3.55 to 4, preferably from 3.55 to 3.8.

These (epi)K5-amine-O-versulfated-derivatives are useful products as intermediates in the preparation of their N-(C<sub>2</sub>-C<sub>4</sub>)acylated derivatives and as active ingredients basically free of activity on the coagulation parameters but having other interesting pharmacobiological properties, useful for the preparation of pharmaceutical compositions. For use of the epiK5-amine-O-versulfate-derivatives of the present invention as active ingredients of pharmaceutical compositions, it is advantageous to prepare both derivatives of low molecular weight, with a mean molecular weight from approximately 3,000 to approximately 11,500, preferably from approximately 4,500 to approximately 8,500, with a molecular weight distribution of between approximately 1,000 and approximately 15,000, preferably between approximately 2,000 and approximately 10,000 and derivatives of high molecular weight, originating from the unfractionated K5, with a mean molecular weight from approximately 15,000 to approximately 45,000, preferably between approximately 20,000 and approximately 45,000, with a molecular weight distribution from approximately 2,000 to approximately 70,000.

Thus, according to another of its aspects the invention provides new active ingredients of pharmaceutical compositions consisting of (epi)K5-amine-O-versulfate-derivatives consisting of chain mixtures in which at least 90% of said chains have the formula II




in which n is a integer from 2 to 100, preferably from 3 to 100, R, R' and R" are hydrogen or SO<sub>3</sub><sup>-</sup>, the uronic units are all of glucuronic acid, for a sulfation degree of at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9, or are 20-60% consisting of iduronic acid, for a sulfation degree of at least 3.4, advantageously of at least 3.5, more advantageously from 3.55 to 4, preferably from 3.55 to 3.8 and the corresponding cation is chemically or pharmaceutically acceptable.

Advantageous epiK5-amine-O-versulfated-derivatives of extremely high degree of sulfation are consisting of a chain mixture in which at least 90% of said chains have the formula II in which the uronic units are 40-60% consisting of iduronic acid, n is a integer from 2 to 100, preferably from 3 to 100, with a mean molecular weight from approximately 2,000 to approximately 40,000, advantageously from approximately 4,500 to approximately 40,000, R is at least 40%, preferably 50-80% SO<sub>3</sub><sup>-</sup>, R' and R" are both SO<sub>3</sub><sup>-</sup> or one is hydrogen and the other is 5-10% SO<sub>3</sub><sup>-</sup> in monosulfate glucuronic acid and 10-15% SO<sub>3</sub><sup>-</sup> in monosulfate iduronic acid, the degree of sulfation is more than 3.4 and the corresponding cation is chemically or pharmaceutically acceptable.

Preferred epiK5-amine-O-versulfate-derivatives of very high degree


of sulfation are the LMW-epiK5-amine-O-versulfates consisting of a chain mixture in which at least 90% of said chains have the formula II'



in which q is a integer from 2 to 20, R, R' and R" are hydrogen or SO<sub>3</sub><sup>-</sup>, the uronic units are 20-60% comprised, preferably 40-60%, of iduronic acid, for a degree of sulfation from 3.55 to 4, and the corresponding cation is one chemically or pharmaceutically acceptable ion.


Are particularly interesting the chain mixtures of formula II' in which the uronic units are 40-60% comprised, preferably 50-55%, of iduronic acid, R is at least 40%, advantageously 50-80%, preferably approximately 65% SO<sub>3</sub><sup>-</sup>, R' and R" are both SO<sub>3</sub><sup>-</sup> or one is hydrogen and the other is 5-10% SO<sub>3</sub><sup>-</sup> in glucuronic acid and 10-15% SO<sub>3</sub><sup>-</sup> in iduronic acid, n is a integer from 3 to 1.5, with a mean molecular weight from approximately 4,000 to approximately 8,000 and the corresponding cation is chemically or pharmaceutically acceptable.

Among these LMW-epiK5-amine-O-versulfates are preferred those consisting of a chain mixture in which the preponderant species has the formula II'a




in which p is a integer from 4 to 8, R, R' and R" are as defined above, the degree of sulfation is from 3.55 to 4 and the corresponding cation is chemically or pharmaceutically acceptable.

The origin of the new LMW-epiK5-amine-O-versulfated from LMW-epiK5-N-sulfates obtained by nitrous depolymerization and subsequent reduction with, for example, sodium borohydride, involves, at the reducing end of the majority of the chains in said chain mixture, the presence of a sulfated 2,5-anhydromannitol unit of structure (a')




in which R'' represents hydrogen or SO3-.

Thus, the reducing end of the majority of the chains in said chain mixture is represented by the structure (b')



in which the uronic unit can be glucuronic or iduronic.


Among the aforesaid new LMW-epiK5-amine-O-versulfates, are preferred those consisting of mixtures in which the preponderant species is a compound of formula II'b



in which R, R' and R'' are hydrogen or SO3-, X'' is OH or OSO3-, m is 4, 5 or 6, the uronic units are 40-60% consisting of iduronic acid, for a degree of sulfation from 3.55 to 4, the iduronic units being present alternately, starting with a glucuronic or iduronic unit, and the corresponding cation is one chemically or pharmaceutically


acceptable ion.

According to another of its aspects the invention provides new K5-amine-O-versulfate-derivatives consisting of chain mixtures in which at least 90% of said chains have the formula III




in which n is an integer from 2 to 100, preferably from 3 to 100, R, R' and R'' are hydrogen or SO<sub>3</sub><sup>-</sup>, the degree of sulfation is at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9 and the corresponding cation is chemically or pharmaceutically acceptable.

Preferred K5-amine-O-versulfates are the LMW-K5-amine-O-versulfates consisting of chain mixtures in which at least 90% of said chains have the formula III'



in which q is an integer from 2 to 20, R, R' and R'' represent hydrogen or an SO<sub>3</sub><sup>-</sup> group, for a sulfation degree of at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9 and the corresponding cation is one chemically or pharmaceutically acceptable ion.

Among these LMW-K5-amine-O-versulfates are preferred those consisting of a chain mixture in which the preponderant species has the formula III'a




in which p is an integer from 4 to 8, R, R' and R'' are as defined above, the degree of sulfation is at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9 and the corresponding cation is chemically or pharmaceutically acceptable.

The origin of the new LMW-K5-amine-O-versulfated from LMW-K5-sulfates obtained by nitrous depolymerization and subsequent reduction with, for example, sodium borohydride, involves, at the reducing end of the majority of the chains in said chain mixture, the presence of a sulfated 2,5-anhydromannitol unit of structure (a') as shown above, in which R'' represents hydrogen or SO<sub>3</sub><sup>-</sup>.

Thus, the reducing end of the majority of the chains in said chain mixture is represented by the structure (b') as shown above, in which the uronic unit is still of glucuronic acid.

Among the aforesaid new LMW-K5-amine-O-versulfates, are preferred those consisting of mixtures in which the preponderant species is a compound of formula III'b



in which R, R' and R'' are hydrogen or SO<sub>3</sub><sup>-</sup>, X'' is OH or OSO<sub>3</sub><sup>-</sup>, for a sulfation degree of at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9, m is 4, 5 or 6 and the corresponding cation is one chemically or

pharmaceutically acceptable ion.

These LMW-K5-amine-O-versulfated are new products useful as intermediates in the preparation of their N-sulfated or N-acylated derivatives but themselves have interesting pharmacological properties, in particular as anti-free radicals and microbicides and, as such, constitute new active ingredients of pharmaceutical compositions which constitute therefore an additional aspect of the present invention.

In particular, according to another of its aspects, the invention concerns the use of the aforesaid (epi)K5-amine-O-versulfate-derivatives with a high degree of sulfation for the preparation of new N-substituted epiK5-amine-O-versulfate-derivatives.

The N-acyl-(epi)K5-amine-O-versulfate-derivatives according to the present invention are obtained by subjecting the (epi)K5-amine-O-versulfate-derivatives to the step (c) of the process of the present invention.

Thus, according to one of its additional aspects, the present invention provides new N-acyl(epi)K5-amine-O-versulfate-derivatives obtainable by a process characterized in that

- (a) an (epi)K5-N-sulfate-derivative, in acidic form, is treated with a tertiary or quaternary organic base, letting the reaction mixture to stand for a time period of 30-60 minutes, maintaining the pH of the solution at a value of 7 by addition of said tertiary or quaternary organic base and its salt is isolated with said organic base;
- (b) said salt of organic base of said (epi)K5-N-sulfate-derivative is treated with an O-sulfation reagent in the conditions of O-versulfation;
- (c) the product thus obtained is treated with a functional derivative of a (C<sub>2</sub>-C<sub>4</sub>) carboxylic acid, the N-acyl-(epi)K5-amine-O-versulfate-

derivative thus obtained is isolated. Generally the N-acyl-(epi)K5-amine-O-versulfate-derivative is isolated in sodium salt form and optionally said sodium salt is transformed into another chemically or pharmaceutically acceptable salt.

As occurs for the (epi)K5-amine-O-versulfate-derivatives, also the degree of sulfation of the N-acyl-(epi)K5-amine-O-versulfate-derivatives as obtained above depends on the configuration of the starting (epi)K5-N-sulfate-derivative, since the volume in the disaccharide chain of K5-N-sulfate-derivative, in which the uronic units are comprised exclusively of glucuronic acid, allows a oversulfation which is less than that occurring with the epiK5-N-sulfate-derivative, especially if the epimerization degree of the latter is 40-60% of glucuronic acid and 60-40% of iduronic acid.

In fact, it has been ascertained that, subjecting a K5-N-sulfate-derivative to the aforesaid steps (a)-(c) an N-acyl-K5-amine-O-versulfate-derivative is obtained having a degree of sulfation from 2.2 to 3, advantageously from 2.5 to 3, preferably from 2.7 to 2.9.

Subjecting an epiK5-N-sulfate-derivative to the aforesaid steps (a), (b) and (c) in which the iduronic acid content is 20-60% of the total of the uronic acids, N-acyl-epiK5-amine-O-versulfate-derivatives are obtained having a sulfation degree of at least 3.4, advantageously of at least 3.5, more advantageously from 3.55 to 4, preferably from 3.55 to 3.8.

Thus, according to another of its aspects, the present invention provides new N-acyl-(epi)K5-amine-O-versulfate-derivatives in which the acyl is a (C<sub>2</sub>-C<sub>4</sub>) carboxylic acid, having a mean molecular weight from approximately 2,000 to approximately 45,000, preferably between approximately 4,500 and approximately 40,000, a degree of sulfation as indicated above, said derivatives being basically inactive

on the coagulation parameters but useful active ingredients of pharmaceutical or cosmetic compositions.


For use of the N-acyl-epiK5-amine-O-versulfate-derivatives of the present invention as pharmaceutical or cosmetic products it is advantageous to prepare both derivatives of low molecular weight, with a mean molecular weight from approximately 3,000 to approximately 11,500, preferably from approximately 4,500 to approximately 8,500, with a molecular weight distribution of between approximately 1,000 and approximately 15,000, preferably between approximately 2,000 and approximately 10,000 and derivatives of high molecular weight, originating from the unfractionated K5, with a mean molecular weight from approximately 15,000 to approximately 45,000, preferably between approximately 20,000 and approximately 45,000, with a molecular weight distribution from approximately 2,000 to approximately 70,000.

In the N-acyl-epiK5-amine-O-versulfate-derivatives of the present invention, the degree of sulfation is very high, since on the 4 free hydroxyls available per disaccharide unit, at least 3.4, preferably from 3.5 to 3.8, are sulfated, whereas the nitrogen of the glucosamine is virtually 100% acylated. Besides, the N-acyl-epiK5-amine-O-versulfate-derivatives are 100% 6-O-sulfated and 50-80% 3-O-sulfated in their glucosamine units, 5-10% 3-O-monosulfated in glucuronic units, 10-15% O-monosulfated in iduronic units and 2.3-di-O-sulfated in the remaining uronic units, considering that the degree of sulfation is at least 3.4.

The N-acyl-K5-amine-O-versulfate-derivatives which, as indicated above, have a degree of sulfation from 2.2 to 3, are at least 90% 6-O-sulfated.

According to another of its aspects, the invention provides new N-


acyl-epiK5-amine-O-versulfate-derivatives consisting of chain mixtures in which at least 90% of said chains have the formula IV



in which the uronic units are 20-60% consisting of iduronic acid, n is a integer from 2 to 100, preferably from 3 to 100, R, R' and R'' are hydrogen or SO<sub>3</sub><sup>-</sup>, Z is(C<sub>2</sub>-C<sub>4</sub>)acyl, the degree of sulfation is at least 3.4, advantageously of at least 3.5, more advantageously from 3.55 to 4, preferably from 3.55 to 3.8 and the corresponding cation is chemically or pharmaceutically acceptable.

Advantageous N-acyl-epiK5-amine-O-versulfate-derivatives of extremely high degree of sulfation are consisting of a chain mixture in which at least 90% of said chains have the formula IV in which the uronic units are 40-60% consisting of iduronic acid, n is a integer from 2 to 100, preferably from 3 to 100, with a mean molecular weight from approximately 2,000 to approximately 45,000, advantageously from approximately 4,500 to approximately 45,000, R is at least 40%, preferably 50-80% SO<sub>3</sub><sup>-</sup>, R' and R'' are both SO<sub>3</sub><sup>-</sup> or one is hydrogen and the other is 5-10% SO<sub>3</sub><sup>-</sup> in monosulfate glucuronic acid and 10-15% SO<sub>3</sub><sup>-</sup> in monosulfate iduronic acid, the degree of sulfation is more than 3.4 and the corresponding cation is chemically or pharmaceutically acceptable.


The N-acyl-epiK5-amine-O-versulfate-derivatives of extremely high degree of sulfation of particular interest are N-acyl-LMW-epiK5-amine-O-versulfates consisting of a chain mixture in which at least 90% of said chains have the formula IV'



in which q is a integer from 2 to 20, R, R' and R" represent hydrogen or an SO<sub>3</sub><sup>-</sup>group for a degree of sulfation from 3.55 to 4, Z is (C<sub>2</sub>-C<sub>4</sub>)acyl, and the corresponding cation is one chemically or pharmaceutically acceptable ion.

Chain mixtures of formula IV' in which the uronic units are 40-60% comprised, preferably 50-55%, of iduronic acid, R is at least 40%, advantageously 50-80%, preferably approximately 65% SO<sub>3</sub><sup>-</sup>, R' and R" are both SO<sub>3</sub><sup>-</sup> or one is hydrogen and the other is 5-10% SO<sub>3</sub><sup>-</sup> in glucuronic acid and 10-15% SO<sub>3</sub><sup>-</sup> in iduronic acid, q is a integer from 3 to 15, with a mean molecular weight from approximately 4,500 to approximately 9,000 and the corresponding cation is chemically or pharmaceutically acceptable are preferred.

Other particularly interesting N-acyl-LMW-epiK5-amine-O-versulfates are those of very low molecular weight, consisting of a chain mixture in which the preponderant species is a compound of formula IV'a




in which p is a integer from 4 to 8, R, R' and R" are hydrogen or an SO<sub>3</sub><sup>-</sup> group for a degree of sulfation from 3.55 to 4, Z is (C<sub>2</sub>-C<sub>4</sub>)acyl, and the corresponding cation is one chemically or pharmaceutically acceptable ion.

The origin of the new N-acyl-LMW-epiK5-amine-O-versulfates from


LMW-epiK5-sulfates obtained by nitrous depolymerization and subsequent reduction with, for example, sodium borohydride, involves, at the reducing end of the majority of the chains in said chain mixture, the presence of a sulfated 2,5-anhydromannitol unit of structure (a') defined above, in which R'' represents hydrogen or SO<sub>3</sub><sup>-</sup>.

Thus, the reducing end of the majority of the chains in said chain mixture is represented by the structure (b'')



in which Z represents (C<sub>2</sub>-C<sub>4</sub>)acyl and the uronic unit can be glucuronic or iduronic.

Among the aforesaid new N-acyl-LMW-epiK5-amine-O-versulfates, are preferred those consisting of mixtures in which the preponderant species is a compound of formula IV'b




in which R, R' and R'' are hydrogen or SO<sub>3</sub><sup>-</sup>, Z is (C<sub>2</sub>-C<sub>4</sub>)acyl, X'' is OH or OSO<sub>3</sub><sup>-</sup>, m is 4, 5 or 6, for a degree of sulfation from 3.55 to 4, the uronic units are present alternately, starting with a glucuronic or iduronic unit, and the corresponding cation is one chemically or pharmaceutically acceptable ion.

Said cations are advantageously those of alkaline metals, alkaline-earth metals, of ammonium, (C<sub>1</sub>-C<sub>4</sub>)tetraalkylammonium, aluminum and zinc and, among these, preferably the salts of sodium, calcium and tetrabutylammonium.


In all the N-acyl-epiK5-amine-O-versulfates shown above, in

particular those of formula IV, IV', IV'a, IV'b, as also in the structure b'', the acyl group (Z) is preferably a (C<sub>2</sub>-C<sub>4</sub>)acyl selected among the group consisting of acetyl, (2-carboxy)acetyl, (2-methoxycarbonyl)acetyl, (2-ethoxycarbonyl)acetyl, propionyl, (3-carboxy)propionyl, N-(3-methoxycarbonyl)propionyl and (3-ethoxycarbonyl)propionyl.

According to another of its aspects, the invention provides new N-acyl-K5-amine-O-versulfate-derivatives consisting of chain mixtures in which at least 90% of said chains have the formula V




in which n is a integer from 2 to 100, preferably from 3 to 100, Z is (C<sub>2</sub>-C<sub>4</sub>)acyl, R, R' and R'' are hydrogen or SO<sub>3</sub><sup>-</sup>, the degree of sulfation is at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9 and the corresponding cation is chemically or pharmaceutically acceptable. Particularly interesting are new N-acyl-LMW-K5-amine-O-versulfates consisting of chain mixtures in which at least 90% of said chains have the formula V'



in which q is a integer from 2 to 20, Z is (C<sub>2</sub>-C<sub>4</sub>)acyl, R, R' and R'' represent hydrogen or an SO<sub>3</sub><sup>-</sup> group for a sulfation degree of at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more

advantageously from 2.5 to 3, preferably from 2.7 to 2.9 and the corresponding cation is one chemically or pharmaceutically acceptable ion.


Among these N-acyl-LMW-K5-amine-O-versulfates are preferred those consisting of a chain mixture in which the preponderant species has the formula V'a



in which p is an integer from 4 to 8, Z is (C<sub>2</sub>-C<sub>4</sub>)acyl, R, R' and R'' are as defined above, the degree of sulfation is at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9 and the corresponding cation is chemically or pharmaceutically acceptable.

The origin of the new N-acyl-LMW-K5-amine-O-versulfates from LMW-K5-sulfates obtained by nitrous depolymerization and subsequent reduction with, for example, sodium borohydride, involves, at the reducing end of the majority of the chains in said chain mixture, the presence of a sulfated 2,5-anhydromannitol unit of structure (a') as shown above, in which R" represents hydrogen or SO<sub>3</sub><sup>-</sup>.


Thus, the reducing end of the majority of the chains in said chain mixture is represented by the structure (b'')



in which  $Z$ ,  $R$ ,  $R'$  and  $R''$  are as defined above.

Among the aforesaid new N-acyl-LMW-K5-amine-O-versulfates, are

preferred those consisting of mixtures in which the preponderant species is a compound of formula V'b



in which Z is (C<sub>2</sub>-C<sub>4</sub>)acyl, R, R' and R" are hydrogen or SO<sub>3</sub><sup>-</sup>, X" is OH or OSO<sub>3</sub><sup>-</sup>, for a sulfation degree of at least 2.2, advantageously from 2.2 to 3 or from 2.3 to 3, more advantageously from 2.5 to 3, preferably from 2.7 to 2.9, m is 4, 5 or 6 and the corresponding cation is one chemically or pharmaceutically acceptable ion.

In all the N-acyl-K5-amine-O-versulfates shown above, in particular those of formula V, V', V'a, V'b, as also in the structure b''', the acyl group (Z) is preferably a (C<sub>2</sub>-C<sub>4</sub>)acyl selected among the group consisting of acetyl, (2-carboxy)acetyl, (2-methoxycarbonyl)acetyl, (2-ethoxycarbonyl)acetyl, propionyl, (3-carboxy)propionyl, N-(3-methoxycarbonyl)propionyl and (3-ethoxycarbonyl)propionyl.

Particularly interesting are the N-acyl-K5-amine-O-versulfates shown above in which Z is a (C<sub>2</sub>-C<sub>4</sub>)acyl different from acetyl. Also interesting and particularly active are the N-acyl-K5-amine-O-versulfates shown above, in which Z is acetyl, having a degree of sulfation of 2.7-2.9, preferably of approximately 2.8.

The new N-acyl-(epi)K5-amine-O-versulfate-derivatives, especially in their salts form, are highly anionic products able to capture the free radicals. These can be used in the cosmetics industry as coadjuvants against hair loss or to prepare "anti-ageing" creams, but are above all useful in the pharmaceutical industry, as products for the treatment of dermatitis and as microbicides.

Thus, according to one of its additional aspects, the present invention

provides pharmaceutical compositions including, as one of their active ingredients, a pharmacologically active amount of an N-acyl-(epi)K5-amine-O-versulfate-derivative as shown above or of one of its pharmaceutically acceptable salts, in mixture with a pharmaceutical excipient.

In the pharmaceutical compositions of the present invention for oral, subcutaneous, intravenous, transdermal or topical administration, the active ingredients are preferably administered in the form of dosage units, in mixture with the classic pharmaceutical excipients or vehicles. The dose regimen can vary widely depending on the age, the weight and health condition of the patient. This dose regimen includes the administration of a dose from 1 to 1000 mg, advantageously from 10 to 750 mg, preferably 250 to 500 mg from one to three times a day by intravenous, subcutaneous, oral, transdermal or topical administration. The present invention also provides a cosmetic composition including an effective amount of an N-acyl-(epi)K5-amine-O-versulfated-derivative or one of its pharmaceutically acceptable salts, in mixture with a cosmetic excipient.

Besides, the present invention provides a pharmaceutical composition including, as one of its active ingredients, an (epi)K5-amine-O-versulfate-derivative obtainable according to steps (a) and (b) of the process described above, or one of its pharmaceutically acceptable salts, in mixture with a pharmaceutical excipient. Advantageously, said (epi)K5-amine-O-versulfate-derivative is consisting of a chain mixture in which at least 90% of said chains have the formula II, II', III or III' or in which the preponderant species is a compound of formula IIa, II'a ,III'a or III'b. Preferred active ingredient is a Imw-K5-amine-O-versulfate having a degree of sulfation from 2.2 to 3, advantageously having a mean molecular weight from

approximately 3,500 to approximately 11,000, more advantageously from approximately 3,500 to approximately 5,200 and basically free of N-acetyl and N-sulfate groups.

In the pharmaceutical compositions of the present invention for oral, subcutaneous, intravenous, transdermal or topical administration, the active ingredients (epi)K5-amine-O-versulfate-derivatives are preferably administered in the form of dosage units, in mixture with the classic pharmaceutical excipients or vehicles. The dose regimen can vary widely depending on the age, the weight and health condition of the patient. This dose regimen includes the administration of a dose of an (epi)K5-amine-O-versulfate-derivative from 1 to 1000 mg, advantageously from 10 to 750 mg, preferably 250 to 500 mg from one to three times a day by intravenous, subcutaneous, oral, transdermal or topical administration.

The pharmaceutical compositions including an (epi)K5-amine-O-versulfate-derivative such as those shown above are formulated with the classic excipients suitable for different ways of administration. Particularly advantageous are the formulations in the form of creams, ointments, liniments, gels, foams, balsams, vaginal pessaries, suppositories, solutions or suspensions suitable for local administration.

Finally, the present invention provides a pharmaceutical composition containing, as one of its active ingredients, a pharmacologically active amount of a Imw-(epi)K5-N-sulfate, i.e. of a Imw-K5-N-sulfate or of a Imw-epiK5-N-sulfate as shown above or of one of their pharmaceutically acceptable salts, in mixture with a pharmaceutical excipient.

In the pharmaceutical compositions of the present invention for oral, subcutaneous, intravenous, transdermal or topical administration, the active ingredients are preferably administered in the form of dosage

units, in mixture with the classic pharmaceutical excipients or vehicles. The dose regimen can vary widely depending on the age, the weight and health condition of the patient. This dose regimen includes the administration of a dose from 1 to 1000 mg, advantageously from 10 to 750 mg, preferably 250 to 500 mg from one to three times a day by intravenous, subcutaneous, oral, transdermal or topical administration. According to another of its aspects, the present invention also provides a cosmetic composition containing, as one of its active ingredients, an effective amount of a Imw-K5-N-sulfate or LMW-epiK5-N-sulfate or of one of its pharmaceutically acceptable salts, in mixture with a cosmetic excipient.

Advantageously, said LMW-(epi)K5-N-sulfate-derivative is consisting of a chain mixture in which at least 90% of said chains have the formula I, or I', or in which the preponderant species is a compound of formula I'a, or I'b. Preferred active ingredient is a Imw-(epi)K5-N-sulfate-derivative having a mean molecular weight from approximately 1,000 to approximately 12,000, advantageously from approximately 1,500 to approximately 8,000, preferably from approximately 1,500 to approximately 7,500 and basically free of N-acetyl groups.

A salt selected from the group consisting of salts of alkaline metals or alkaline-earth metals, of ammonium, (C<sub>1</sub>-C<sub>4</sub>)tetraalkylammonium, aluminum or zinc, in particular the salt of sodium, potassium, calcium, magnesium, aluminum or zinc constitutes an effective active ingredient of the compositions of the present invention.

The following examples illustrate the invention without however limiting it.

#### PREPARATION I

##### *LMW-epiK5-N-sulfate*

- a) Epimerization of K5-N-sulfate

2 g of K5 N-sulfate, obtained as described in Example 1, steps (i) and (ii), of WO 02/068477, are dissolved in 120 ml of 25 mM HEPES buffer, pH 7, containing 50 mM CaCl<sub>2</sub>. The solution obtained is made to recirculate through a 50 ml column filled with the resin containing the immobilized enzyme obtained as described in WO 96/14425. This operation is carried out at 30°C with a flow of 200 ml/h for 24 hours. The product obtained is purified through ultrafiltration over a 1000 D membrane and passage over an ionic exchange column IR 120 H<sup>+</sup>, neutralizing the eluate with 1N NaOH. The sample is recovered by precipitation with ethanol or acetone.

An epimerized product is obtained with an iduronic acid/glucuronic acid ratio of 55/45 against a ratio of 0 /100 of the starting product. The percentage of epimerization was calculated with <sup>1</sup>H-RMN according to the method described in WO 96/14425. The yield, calculated by measuring the content of uronic acids against a standard with the carbazole method (Bitter and Muir Anal. Biochem. 39, 88-92-1971) is 90%.

b) *Depolymerization of epi-K5-N-sulfate*

1 g of product obtained in step (a) is depolymerized by the degradation method with nitrous acid and subsequent reduction of the aldehyde which forms. In particular one continues by dissolving the product in 25 ml of distilled water and adding it with 230 mg of sodium nitrite dissolved in 115 ml of distilled water. The solution is then brought to 4°C and the pH to 2 with 0.1 N HCl and maintained for 30 minutes. At the end of the reaction the solution is brought to room temperature and the pH to 7 with 0.1 M NaOH. The solution is then added with 450 mg. of NaBH<sub>4</sub> and reacted for 4 hours. The product is recovered by precipitation with 3 volumes of acetone at 4°C, filtration with filtering funnel and dried at 40° C in a vacuum oven. 900 mg of

LMW-epiK5-N-sulfate are obtained with a molecular weight distribution measured with HPLC method which ranges from 1,000 to 4,000 and with a glucuronic unit content of 45% and iduronic unit content of 55%.

#### PREPARATION II

##### *LMW-K5-N-sulfate*

The product obtained as described in Example 1, steps (i) and (ii), of WO 02/068477 is depolymerized by the degradation method with nitrous acid and subsequent reduction of the aldehyde which forms. One continues by dissolving 1 g of K5-N-sulfate in 200 ml of distilled water and adding it with 480 mg of sodium nitrite dissolved in 240 ml of distilled water. The solution is then brought to 4°C and the pH to 2 with 0.1 N HCl and maintained for 30 minutes. At the end of the reaction the solution is brought to pH 7 with 0.1 M NaOH and then to room temperature. The solution is then added with 450 mg. of NaBH<sub>4</sub> and reacted for 4 hours. The excess NaBH<sub>4</sub> is eliminated with HCl bringing the pH to 5-6. The product, neutralized with 0.1 M NaOH, is recovered by precipitation with 3 volumes of acetone at 4°C, filtration with filtering funnel and dried at 40° C in a vacuum oven. 900 mg of LMW-K5-N-sulfate are obtained with a mean molecular weight of approximately 2,000, consisting of a chain mixture in which the preponderant species is a compound of formula I'b in which m is 4 and the uronic units are those of glucuronic acid.

#### PREPARATION III

##### (a) *Depolymerization of K5-N-sulfate*

2 g of K5-N-sulfate obtained as described in Example 1, steps (i) and (ii), of WO 02/068477 is depolymerized as described in PREPARATION II, utilizing 100 mg of sodium nitrite and 300 mg. of sodium borohydride. 1.8 g. of LMW-K5-N-sulfate are obtained with a mean molecular weight of 5,000

(b) Epimerization of LMW-K5-N-sulfate

1 g of LMW-K5 N-sulfate obtained in step (a) is treated as described in step (a) of the Example 1. An epimerized product is obtained with an iduronic acid/glucuronic acid ratio of 44/56 against a ratio of 0/100 of the starting product, with a molecular weight distribution from 2,000 to 10,000 and with a mean molecular weight of 5,000 D. The yield, calculated by measuring the content of uronic acids against a standard with the carbazole method (Bitter and Muir Anal. Biochem. 39, 88-92-1971) is 90%.

#### PREPARATION IV

##### Preparation of an epiK5-N-sulfate

A solution of 10 g of K5-N-sulfate obtained as described in Example 1, steps (i) and (ii), of WO 02/068477 in 600 ml of 25 mM HEPES buffer at pH 7, containing  $\text{CaCl}_2$  at a concentration of 50 mM is made to recirculate through a 50 ml column filled with Sepharose 4B resin containing 5 g of recombinant C5-epimerase (WO 96/14425) immobilized as described in WO 01/72848. The reaction is carried out at 30°C at pH 7 with a flow of 200 ml/h for 24 hours. The product obtained is purified by ultrafiltration and precipitation with ethanol. Thus an epiK5-N-sulfate is obtained whose iduronic acid content is 54%.

#### PREPARATION V

##### Preparation of a lmw-epiK5-N-sulfate

1 g of product obtained in PREPARATION IV is depolymerized by the degradation method with nitrous acid and subsequent reduction of the aldehyde which forms. In particular one continues by dissolving the product in 25 ml of distilled water and adding it with 230 mg of sodium nitrite dissolved in 115 ml of distilled water. The solution is then brought to 4°C and the pH to 2 with 0.1 N HCl and maintained for 30

minutes. At the end of the reaction the solution is brought to room temperature and the pH to 7 with 0.1 M NaOH. The solution is then added with 450 mg. of NaBH<sub>4</sub> and reacted for 4 hours. The product is recovered by precipitation with 3 volumes of acetone at 4°C, filtration with filtering funnel and dried at 40° C in a vacuum oven. 900 mg of LMW-epiK5-N-sulfate are obtained with a molecular weight distribution measured with HPLC method which ranges from 1,000 to 4,000.

#### EXAMPLE 1

##### *EpiK5-amine-O-versulfate*

###### *(a) Tetrabutylammonium salt of epi K5-N-sulfate*

A solution of 400 mg of epiK5-N-sulfate with an iduronic acid content of 54% as obtained in PREPARATION IV in 40 ml of water is thermostated at 4°C, then passed over an ionic exchange resin IR 120 H<sup>+</sup> preconditioned with water at 4°C. The eluate obtained, consisting of 100 ml of a solution at pH 1.94, is neutralized with a solution of 15% tetrabutylammonium hydroxide and left at room temperature for one hour, maintaining the pH at 7 by addition of 15% tetrabutylammonium hydroxide and finally is lyophilized. Thus 805 mg of tetrabutylammonium salt of epiK5-N-sulfate are obtained.

###### *(b) Epi-K5-amine-O-versulfate*

To a solution containing the 805 mg of the salt thus obtained in 30 ml of dimethylformamide is set at 55°C and treated with 30 ml of dimethylformamide containing 2.26 g of pyridine.SO<sub>3</sub> adduct. The reaction at 55°C is continued overnight then 60 ml of water are added to the mixture. After neutralization with 1N NaOH, the product is precipitated with 3 volumes of acetone saturated with NaCl and set at 4°C overnight. The precipitate is recovered by filtration on guch G4 and then ultrafiltered with 1000 D Millipore TFF system and dried at reduced pressure. 550 mg of epi-K5-amine-O-versulfated are

obtained having a content of iduronic acid of 54%, of glucosamine-6-O-sulfate of 100%, of glucosamine 3-O-sulfate of 60%, of monosulfate glucuronic acid of 10%, of monosulfate iduronic acid of 15%, the rest of the uronic units being disulfated, with a sulfation degree of 3.55 measured with the conductometric method according to Casu et al. 1975.

#### EXAMPLE 2

##### *N-Acetyl-epiK5-amine-O-versulfate*

To a solution of 250 mg of epi-K5-amine-O-versulfate obtained in Example 1 in 75 ml of water and cooled to 4°C are added 7.5 ml of methanol and 3.75 ml of acetic anhydride. The reaction is kept at 4°C for 2 hours maintaining the pH at a value of 7 with 5M NaOH. After ultrafiltration on 1,000 D membrane are added 3 volumes of acetone saturated with sodium chloride and the precipitate is recovered by centrifugation at 5,000 rpm for 5'. Thus 249 mg of N-acetyl-epiK5-amine-O-versulfated are obtained with an iduronic acid content of 54%, glucosamine-6-O-sulfate of 100%, N-acetyl of 100%, glucosamine 3-O-sulfate of 60%, monosulfate glucuronic acid of 10%, monosulfate iduronic acid of 15%, the rest of the uronic units being disulfated, and whose sulfation degree is 3.5 measured with the conductometric method according to Casu et al. 1975.

#### EXAMPLE 3

##### *N-acetyl-K5-amine-O-versulfate*

1 gr of K5 N,O oversulfate obtained in Example 2 of WO/02068477 is dissolved in 200 ml of water and the solution is brought to pH 2 with 1 N HCl and thermostated at 50°C. The reaction is kept at 50 °C for 3 hours and then cooled to room temperature and neutralized with 1N NaOH. The sample is then cooled to 4°C and 20 ml of MeOH and 10 ml of acetic anhydride are added to the reaction which is left at 4°C for 2

hours maintaining the pH constantly at 7. At the end of the reaction the sample is purified from salts by ultrafiltration on a membrane with a 1000 D cut off and then recovered by dried at reduced pressure. A 100% N-acetylated product is obtained, 100% 6-O sulfate, 30% monosulfate and 70% disulfate on the glucuronic acid is obtained.

## CLAIMS

1. Process for the preparation of N-acyl-(epi)K5-amine-O-versulfate-derivatives and of its chemically or pharmaceutically acceptable salts, characterized in that
  - (a) an (epi)K5-N-sulfate-derivative, in acidic form, is treated with a tertiary or quaternary organic base, letting the reaction mixture to stand for a time period of 30-60 minutes, maintaining the pH of the solution at a value of approximately 7 and its salt is isolated with said organic base;
  - (b) said salt of organic base of said (epi)K5-N-sulfate-derivative is treated with an O-sulfation reagent in the conditions of O-versulfation;
  - (c) the (epi)K5-amine-O-versulfate-derivative thus obtained is treated with a functional derivative of a (C<sub>2</sub>-C<sub>4</sub>) carboxylic acid, the N-acyl-(epi)K5-amine-O-versulfate-derivative is isolated.
2. Process according to claim 1, characterized in that said N-acyl-(epi)K5-N,O-versulfate-derivative is isolated in sodium salt form and optionally transformed into another chemically or pharmaceutically acceptable salt.
3. Process according to anyone of claims 1 and 2, characterized in that, in step (a) tetrabutylammonium hydroxide is used as an organic base.
4. Process according to anyone of claims from 1 to 3, characterized in that, in step (b) the O-versulfation is carried out in dimethylformamide utilizing 2-4 moles of O-sulfation reagent per available OH per disaccharide at a temperature of 40-60°C for 15-20 hours.
5. Process according to anyone of claims from 1 to 4, characterized in that as starting material an (epi)K5-N-sulfate-derivative is used having

a mean molecular weight from approximately 1,000 to approximately 25,000.

6. Process according to anyone of claims from 1 to 5, characterized in that said starting material is 40-60% C5-epimerized.


7. Process according to anyone of claims from 1 to 6, characterized in that said starting material has a mean molecular weight from approximately 1,500 to approximately 25,000.

8. Process according to claim 7, characterized in that said starting material has a mean molecular weight between 10,000 and 25,000.

9. Process according to claim 7, characterized in that said starting material has a mean molecular weight from approximately 1,500 to approximately 12,000.

10. Process according to claim 9, characterized in that said starting material has a mean molecular weight from approximately 1,500 to approximately 8,000.

11. Process according to claim 5, characterized in that as starting material an (epi)K5-N-sulfate-derivative is used consisting of a chain mixture in which at least 90% of said chains have the formula I




in which the glucuronic units/iduronic units ratio is from 100/0 to 40/60, n is an integer from 2 to 100 and the corresponding cation is chemically or pharmaceutically acceptable.

12. Process according to claim 11, characterized in that said starting material is consisting of a chain mixture in which at least 90% of said chains have the formula I, in which the uronic units are 40-60%

consisting of iduronic acid.


13. Process according to claim 11, characterized in that said starting material is a Imw-(epi)K5-N-sulfate consisting of a chain mixture in which at least 90% of said chains have the formula I in which the uronic units are all consisting of glucuronic acid or are 40-60% consisting of iduronic acid, n is a integer from 3 to 15 and the corresponding cation is chemically acceptable.

14. Process according to claim 11, characterized in that said starting material is a Imw-(epi)K5-N-sulfate consisting of a chain mixture in which at least 90% of said chains have the formula I'



in which the uronic units are 100% consisting of glucuronic acid or 60-40% of glucuronic acid and 40-60% of iduronic acid, q is a integer from 2 to 20 and the corresponding cation is chemically or pharmaceutically acceptable.


15. Process according to claim 11, characterized in that said starting material is a Imw-(epi)K5-N-sulfate consisting of a chain mixture in which the preponderant species has the formula I'a



in which the uronic units are 100% consisting of glucuronic acid or 60-40% glucuronic and 40% to 60% of iduronic acid, p is a integer from 4 to 8.


16. Process according to anyone of claims from 5 to 15, characterized in that said starting material is a lmw-(epi)K5-N-sulfate obtained by nitrous depolymerization of the corresponding (epi)K5-N-sulfate and subsequent reduction.

17. Process according to claim 16, characterized in that said starting LMW-(epi)K5-N-sulfate contains, at the reducing end of the majority of the chains in said chain mixture, a 2,5-anhydromanno unit of structure (a)



in which X represents a hydroxymethyl group.

18. Process according to anyone of claims 16 and 17, characterized in that as starting material a lmw-(epi)K5-N-sulfate is used consisting of chain mixtures in which the preponderant species is a compound of formula I'b



in which X is hydroxymethyl, m is 4, 5 or 6, the corresponding cation is one chemically or pharmaceutically acceptable ion, the uronic units are all of glucuronic acid or the glucuronic and iduronic units are present alternately, starting with a glucuronic or iduronic unit.

19. Process according to anyone of claims from 1 to 18, characterized in that said starting (epi)K5-N-sulfate-derivative is utilized in sodium salt form.

20. An N-acyl-(epi)K5-amine-O-versulfate-derivative obtainable according to the process of claims from 1 to 19.

21. An N-acyl-(epi)K5-amine-O-versulfate-derivative according to claim 20 in salt form of an alkaline metal or alkaline-earth metal, of ammonium, (C<sub>1</sub>-C<sub>4</sub>)tetraalkylammonium, aluminum or zinc.


22. An N-acyl-epiK5-amine-O-versulfate-derivative, in which acyl is a (C<sub>2</sub>-C<sub>4</sub>)acyl, having an iduronic acid content of 20-60%, a mean molecular weight from approximately 2,000 to approximately 45,000 and a sulfation degree of at least 3.4, or one of its chemically or pharmaceutically acceptable salts.

23. An N-acyl-epiK5-amine-O-versulfate-derivative according to claim 22, whose mean molecular weight is between approximately 15,000 and approximately 45,000.

24. An N-acyl-epiK5-amine-O-versulfate-derivative according to claim 22, whose mean molecular weight is between approximately 4,500 and approximately 8,500.

25. An N-acyl-epiK5-amine-O-versulfate-derivative according to anyone of claims from 22 to 24, characterized in that said degree of sulfation is from 3.4 to 3.8.

26. An N-acyl-epiK5-amine-O-versulfate-derivative consisting of chain mixtures in which at least 90% of said chains have the formula IV




in which the uronic units are 20-60% consisting of iduronic acid, n is a integer from 2 to 100, R, R' and R'' are hydrogen or SO<sub>3</sub><sup>-</sup>, Z is(C<sub>2</sub>-C<sub>4</sub>)acyl, the degree of sulfation is at least 3.4 and the corresponding cation is chemically or pharmaceutically acceptable.

27. An N-acyl-epiK5-amine-O-versulfate-derivative according to

claim 26, characterized in that it consists of a chain mixture in which at least 90% of said chains have the formula IV in which the uronic units are 40-60% consisting of iduronic acid, n is a integer from 3 to 100, with a mean molecular weight from approximately 2,000 to approximately 45,000, R is at least 40% SO<sub>3</sub><sup>-</sup>, R' and R" are both SO<sub>3</sub><sup>-</sup> or one is hydrogen and the other is 5-10% SO<sub>3</sub><sup>-</sup> in monosulfate glucuronic acid and 10-15% SO<sub>3</sub><sup>-</sup> in monosulfate iduronic acid and the corresponding cation is chemically or pharmaceutically acceptable.

28. An N-acyl-epiK5-amine-O-versulfate-derivative according to anyone of claims 26 and 27, characterized in that it is a Imw-N-acyl-epiK5-O-versulfate consisting of a chain mixture in which at least 90% of said chains have the formula IV'




in which q is a integer from 2 to 20, R, R' and R" represent hydrogen or an SO<sub>3</sub><sup>-</sup> group for a degree of sulfation from 3.55 to 4, Z is (C<sub>2</sub>-C<sub>4</sub>)acyl, and the corresponding cation is chemically or pharmaceutically acceptable.

29. A Imw-N-acyl-epiK5-O-versulfate according to claim 28, characterized in that in said chain mixture of formula IV' the uronic units are 50-55% consisting of iduronic acid, R is at least 40% SO<sub>3</sub><sup>-</sup>, R' and R" are both SO<sub>3</sub><sup>-</sup> or one is hydrogen and the other is 5-10% SO<sub>3</sub><sup>-</sup> in glucuronic acid and 10-15% SO<sub>3</sub><sup>-</sup> in iduronic acid, q is a integer from 3 to 15, with a mean molecular weight from approximately 4,500 to approximately 9,000 and the corresponding cation is chemically or pharmaceutically acceptable.


30. A Imw-N-acyl-epiK5-O-versulfate according to anyone of claims

28 and 29, characterized in that it consists of a chain mixture in which the preponderant species is a compound of formula IV'a



in which p is a integer from 4 to 8, R, R' and R'' are hydrogen or an SO<sub>3</sub><sup>-</sup> group for a degree of sulfation from 3.55 to 4, Z is (C<sub>2</sub>-C<sub>4</sub>)acyl, and the corresponding cation is chemically or pharmaceutically acceptable.

31. A Imw-N-acyl-epiK5-O-versulfate according to claim 30, characterized in that said preponderant species is a compound of formula IV'b




in which R, R' and R'' are hydrogen or SO<sub>3</sub><sup>-</sup>, Z is (C<sub>2</sub>-C<sub>4</sub>)acyl, X'' is OH or OSO<sub>3</sub><sup>-</sup>, m is 4, 5 or 6, for a degree of sulfation from 3.55 to 4, the uronic units are present alternately, starting with a glucuronic or iduronic unit, and the corresponding cation is chemically or pharmaceutically acceptable.

32. A Imw-N-acyl-epiK5-O-versulfate according to any of claims from 22 to 31 in which the substituent (C<sub>2</sub>-C<sub>4</sub>)acyl is selected from the group consisting of acetyl, (2-carboxy)acetyl, (2-methoxycarbonyl)acetyl, (2-ethoxycarbonyl)acetyl, propionyl, (3-carboxy)propionyl, N-(3-methoxycarbonyl)propionyl and (3-ethoxycarbonyl)propionyl.

33. An N-acyl-epiK5-amine-O-versulfate-derivative according to anyone of claims from 22 to 32, characterized in that said salt or


corresponding cation is an alkaline metal or alkaline-earth metal, of ammonium, (C<sub>1</sub>-C<sub>4</sub>)tetraalkylammonium, aluminum or zinc.

34. An N-acyl-K5-amine-O-versulfate-derivative consisting of a chain mixture in which at least 90% of said chains have the formula V




in which n is a integer from 2 to 100, Z is (C<sub>2</sub>-C<sub>4</sub>)acyl, R, R' and R'' are hydrogen or SO<sub>3</sub><sup>-</sup>, the degree of sulfation is at least 2.2, and the corresponding cation is chemically or pharmaceutically acceptable.

35. An N-acyl-K5-amine-O-versulfate-derivative according to claim 34, characterized in that it is a Imw-N-acyl-K5-amine-O-versulfate consisting of a chain mixture in which at least 90% of said chains have the formula V'




in which q is a integer from 2 to 20, Z is (C<sub>2</sub>-C<sub>4</sub>)acyl, R, R' and R'' represent hydrogen or an SO<sub>3</sub><sup>-</sup> group for a degree of sulfation from 2.2 to 3, and the corresponding cation is chemically or pharmaceutically acceptable.

36. A Imw-N-acyl-K5-amine-O-versulfate according to claim 35, characterized in that it consists of a chain mixture in which the preponderant species is a compound of formula V'a



in which  $p$  is an integer from 4 to 8,  $Z$  is  $(C_2-C_4)$ acyl,  $R$ ,  $R'$  and  $R''$  represent hydrogen or an  $SO_3^-$  group for a degree of sulfation from 2.2 to 3, and the corresponding cation is chemically or pharmaceutically acceptable.

37. A Imw-N-acyl-K5-amine-O-versulfate according to claim 36, characterized in that said preponderant species is a compound of formula V'b



in which  $Z$  is  $(C_2-C_4)$ acyl,  $R$ ,  $R'$  and  $R''$  are hydrogen or  $SO_3^-$ ,  $X'$  is OH or  $OSO_3^-$ , for a degree of sulfation from 2.2 to 3,  $m$  is 4, 5 or 6 and the corresponding cation is one chemically or pharmaceutically acceptable ion.

38. An N-acyl-K5-amine-O-versulfate-derivative according to anyone of claims from 34 to 37, characterized in that said degree of sulfation is from 2.3 to 3.


39. An N-acyl-K5-amine-O-versulfate-derivative according to claim 38, characterized in that said degree of sulfation is from 2.5 to 3.

40. An N-acyl-K5-amine-O-versulfate-derivative according to claim 39, characterized in that said degree of sulfation is from 2.7 to 2.9.

41. An N-acyl-K5-amine-O-versulfate-derivative according to anyone of claims from 34 to 40, in which the substituent  $(C_2-C_4)$ acyl is different

from acetyl.


42. An N-acyl-K5-amine-O-versulfate-derivative according to anyone of claims from 34 to 40, in which the substituent ( $C_2-C_4$ )acyl is acetyl, having a degree of sulfation of 2.7-2.9.
43. An N-acyl-K5-amine-O-versulfate-derivative according to claim 42, having a degree of sulfation of approximately 2.8.
44. An N-acyl-K5-amine-O-versulfate-derivative according to anyone of claims from 34 to 43, characterized in that said salt or corresponding cation is an alkaline metal or alkaline-earth metal, of ammonium, ( $C_1-C_4$ )tetraalkylammonium, aluminum or zinc.
45. Pharmaceutical composition including, as one of its active ingredients, an (epi)K5-amine-O-versulfate-derivative or one of its pharmaceutically acceptable salts, obtainable by the process according to steps (a) and (b) of the claim 1, isolated in sodium salt form and optionally transformed into another pharmaceutically acceptable salt, in mixture with a pharmaceutical excipient.
46. Composition according to claim 45, characterized in that said active ingredient is an (epi)K5-amine-O-versulfate-derivative having a mean molecular weight from approximately 4,500 to approximately 40,000.
47. Pharmaceutical composition according to anyone of claims 45 and 46, in which said active ingredient is an (epi)K5-amine-O-versulfate-derivative consisting of a chain mixture in which at least 90% of said chains have the formula II



in which n is a integer from 2 to 100, R, R' and R'' are hydrogen or  $SO_3^-$ ,

the uronic units are all of glucuronic acid, for a degree of sulfation from 2.2 to 3, or are 20-60% consisting of iduronic acid, for a sulfation degree of at least 3.4, and the corresponding cation is pharmaceutically acceptable.


48. Pharmaceutical composition according to claim 47, characterized in that said active ingredient is a LMW-epiK5-amine-O-versulfate consisting of a chain mixture in which at least 90% of said chains have the formula II'



in which q is an integer from 2 to 20, R, R' and R" are hydrogen or SO<sub>3</sub><sup>-</sup>, the uronic units are 20-60% comprised, preferably 40-60%, of iduronic acid, for a degree of sulfation from 3.55 to 4.


49. Pharmaceutical composition according to claim 48, characterized in that, in said chain mixture of formula II', the uronic units are 40-60% consisting of iduronic acid, R is at least 40% SO<sub>3</sub><sup>-</sup>, R' and R" are both SO<sub>3</sub><sup>-</sup> or one is hydrogen and the other is 5-10% SO<sub>3</sub><sup>-</sup> in glucuronic acid and 10-15% SO<sub>3</sub><sup>-</sup> in iduronic acid, n is an integer from 3 to 15, with a mean molecular weight from approximately 4,000 to approximately 8,000.

50. Pharmaceutical composition according to anyone of claims 48 and 49, characterized in that said LMW-epiK5-amine-O-versulfate is consisting of a chain mixture in which the preponderant species has the formula II'a




in which p is a integer from 4 to 8, R, R' and R" are as defined above, the degree of sulfation is from 3.55 to 4 and the corresponding cation is pharmaceutically acceptable.

51. Pharmaceutical composition according to claim 50, characterized in that said preponderant species is a compound of formula II'b



in which R, R' and R" are hydrogen or SO<sub>3</sub><sup>-</sup>, X'' is OH or OSO<sub>3</sub><sup>-</sup>, m is 4, 5 or 6, the uronic units are 40-60% consisting of iduronic acid, for a degree of sulfation from 3.55 to 4, the iduronic units being present alternately, starting with a glucuronic or iduronic unit, and the corresponding cation is one pharmaceutically acceptable ion.


52. Pharmaceutical composition according to claim 45 including, as one of its active ingredients, a K5-amine-O-versulfate-derivative consisting of a chain mixture in which at least 90% of said chains have the formula III



in which n is a integer from 2 to 100, R, R' and R" are hydrogen or SO<sub>3</sub><sup>-</sup>, the degree of sulfation is at least 2.2, and the corresponding cation is


pharmaceutically acceptable.

53. Pharmaceutical composition according to claim 52, characterized in that said active ingredient is a LMW-K5-amine-O-versulfate consisting of a chain mixture in which at least 90% of said chains have the formula III'




in which q is an integer from 2 to 20, R, R' and R'' represent hydrogen or an SO<sub>3</sub><sup>-</sup> group for a sulfation degree of at least 2.2.

54. Pharmaceutical composition according to claim 53, characterized in that said LMW-K5-amine-O-versulfate is consisting of a chain mixture in which the preponderant species has the formula III'a



in which p is an integer from 4 to 8, R, R' and R'' are as defined above, the degree of sulfation is from 2.2 to 3.

55. Pharmaceutical composition according to claim 50, characterized in that said preponderant species is a compound of formula III'b



in which R, R' and R'' are hydrogen or SO<sub>3</sub><sup>-</sup>, X'' is OH or OSO<sub>3</sub><sup>-</sup>, for a degree of sulfation from 2.2 to 3, m is 4, 5 or 6 and the corresponding

cation is one pharmaceutically acceptable ion.

56. Pharmaceutical composition according to anyone of claims from 45 to 55, characterized in that said pharmaceutically acceptable salt or cation is sodium, potassium, calcium, magnesium or zinc.

57. Pharmaceutical composition according to anyone of claims from 45 to 56, characterized in that it is in the form of cream, ointment, liniment, gel, foam, balsam, vaginal pessary, suppository, solution or suspension for local administration.

58. A pharmaceutical composition containing, as one of its active ingredients, a pharmacologically active amount of a Imw-(epi)K5-N-sulfate basically free of acetyl groups, or of one of its pharmaceutically acceptable salts, in mixture with a pharmaceutical excipient.

59. A cosmetic composition containing an effective amount of a Imw-(epi)K5-N-sulfate according to anyone of claims from 1 to 10 and from 25 to 37, in which said salt or cation is pharmaceutically acceptable, in mixture with a cosmetic excipient.

1/3




Fig. 1




Fig. 2

3/3



Fig. 3

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/IB 03/02339

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 C08B37/00 C08B37/08 C08B37/10 A61K31/726 A61K31/727  
 A61K31/737

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 C08B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data, EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 544 592 A (SANOFI ELF) 2 June 1993 (1993-06-02) cited in the application  abstract; claims page 10, line 42 -page 12, line 21 page 21, line 42 -page 22, line 60 examples 4,5 ---	1,11, 14-16, 20,26, 28,34, 45-58
A	WO 01 72848 A (CIPOLLETTI GIOVANNI ; PASQUA ORESTE (IT); INALCO SPA (IT); ZOPPETTI) 4 October 2001 (2001-10-04) cited in the application page 9, line 30 -page 10, line 4 claims; examples ---	1,45,58 ---

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

21 October 2003

Date of mailing of the international search report

05/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mazet, J-F

## INTERNATIONAL SEARCH REPORT

International	application No
PCT/IB 03/02339	

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 43317 A (CIPOLLETTI GIOVANNI ; PASQUA ORESTE (IT); INALCO SPA (IT); ZOPPETTI) 20 November 1997 (1997-11-20) cited in the application page 6, line 27 -page 7, line 2 claims -----	1, 45, 58
A	WO 98 09636 A (TORRI GIANGIACOMO ; NAGGI ANNAMARIA (IT); ISTITUTO SCIENT DI CHIMIC) 12 March 1998 (1998-03-12) page 3, line 27 -page 5, line 20; example 1 claims -----	45-57
A	WO 98 34958 A (CIPOLLETTI GIOVANNI ; PASQUA ORESTE (IT); INALCO SPA (IT); ZOPPETTI) 13 August 1998 (1998-08-13) cited in the application page 1, line 25 -page 2, line 22 -----	22-27, 34, 38-40, 42, 43
A	US 5 550 116 A (LORMEAU JEAN CLAUDE ET AL) 27 August 1996 (1996-08-27) cited in the application examples 6, 7 column 34, line 27 -column 35, line 65 -----	1
A	EP 0 489 647 A (SANOFI ELF) 10 June 1992 (1992-06-10) -----	
A	NAGGI A ET AL: "TOWARD A BIOTECHNOLOGICAL HEPARIN THROUGH COMBINED CHEMICAL AND ENZYMIC MODIFICATION OF THE ESCHERICHIA COLI K5 POLYSACCHARIDE" SEMINARS IN THROMBOSIS AND HEMOSTASIS, STUTTGART, DE, vol. 27, no. 5, 2001, pages 437-443, XPO08004483 ISSN: 0094-6176 the whole document -----	1

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No
PCT/IB 03/02339

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
EP 0544592	A 02-06-1993		FR 2684385 A1 AT 176484 T CA 2083576 A1 DE 69228362 D1 DE 69228362 T2 DK 544592 T3 EP 0544592 A2 ES 2129037 T3 HU 64087 A2 JP 5271305 A MX 9206783 A1 US 5384398 A US 5314876 A	04-06-1993 15-02-1999 29-05-1993 18-03-1999 09-09-1999 20-09-1999 02-06-1993 01-06-1999 29-11-1993 19-10-1993 31-05-1994 24-01-1995 24-05-1994
WO 0172848	A 04-10-2001		IT MI20000665 A1 AU 4651001 A CA 2404478 A1 CN 1422283 T WO 0172848 A1 EP 1268559 A1 US 2003023079 A1 US 2002062019 A1	01-10-2001 08-10-2001 04-10-2001 04-06-2003 04-10-2001 02-01-2003 30-01-2003 23-05-2002
WO 9743317	A 20-11-1997		IT MI960956 A1 AT 210154 T AU 3026597 A DE 69708862 D1 DE 69708862 T2 DK 897393 T3 WO 9743317 A1 EP 0897393 A1 ES 2167748 T3 US 6162797 A	10-11-1997 15-12-2001 05-12-1997 17-01-2002 14-08-2002 02-04-2002 20-11-1997 24-02-1999 16-05-2002 19-12-2000
WO 9809636	A 12-03-1998		IT MI961840 A1 AT 241367 T AU 715868 B2 AU 4456197 A DE 69722450 D1 WO 9809636 A1 EP 0956027 A1 JP 2000517328 T NZ 334566 A PL 331798 A1 RU 2176915 C2	06-03-1998 15-06-2003 10-02-2000 26-03-1998 03-07-2003 12-03-1998 17-11-1999 26-12-2000 28-01-2000 02-08-1999 20-12-2001
WO 9834958	A 13-08-1998		IT MI970252 A1 AT 211488 T AU 723168 B2 AU 6394398 A DE 69803362 D1 DE 69803362 T2 DK 958307 T3 WO 9834958 A1 EP 0958307 A1 ES 2169503 T3 JP 2001510502 T NZ 337399 A	07-08-1998 15-01-2002 17-08-2000 26-08-1998 28-02-2002 14-08-2002 22-04-2002 13-08-1998 24-11-1999 01-07-2002 31-07-2001 28-01-2000

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

PCT/IB 03/02339

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9834958	A	PT US	958307 T 6288044 B1	28-06-2002 11-09-2001
US 5550116	A 27-08-1996	FR AT AU AU BG BG BR CA CS DE DE DK EP ES FI GR HU IE IL JP KR MX NO NZ PL PT SI SK RU ZA	2669932 A1 150033 T 646112 B2 8836191 A 60479 B1 95567 A 9105239 A 2056878 A1 9103668 A3 69125109 D1 69125109 T2 489647 T3 0489647 A2 2099145 T3 915697 A 3023541 T3 60784 A2 914197 A1 100229 A 5001101 A 214752 B1 9102353 A1 914751 A 240838 A 292624 A1 99671 A ,B 9111886 A ,B 280642 B6 2099353 C1 9109518 A	05-06-1992 15-03-1997 10-02-1994 04-06-1992 31-05-1995 31-03-1994 18-08-1992 04-06-1992 16-09-1992 17-04-1997 28-08-1997 08-09-1997 10-06-1992 16-05-1997 04-06-1992 29-08-1997 28-10-1992 03-06-1992 04-01-1998 08-01-1993 02-08-1999 01-06-1992 04-06-1992 25-11-1993 08-03-1993 30-10-1992 28-02-1998 16-05-2000 20-12-1997 26-08-1992
EP 0489647	A 10-06-1992	FR AT AU AU BG BG BR CA CS DE DE DK EP ES FI GR HU IE IL JP KR MX NO NZ	2669932 A1 150033 T 646112 B2 8836191 A 60479 B1 95567 A 9105239 A 2056878 A1 9103668 A3 69125109 D1 69125109 T2 489647 T3 0489647 A2 2099145 T3 915697 A 3023541 T3 60784 A2 914197 A1 100229 A 5001101 A 214752 B1 9102353 A1 914751 A 240838 A	05-06-1992 15-03-1997 10-02-1994 04-06-1992 31-05-1995 31-03-1994 18-08-1992 04-06-1992 16-09-1992 17-04-1997 28-08-1997 08-09-1997 10-06-1992 16-05-1997 04-06-1992 29-08-1997 28-10-1992 03-06-1992 04-01-1998 08-01-1993 02-08-1999 01-06-1992 04-06-1992 25-11-1993

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No

PCT/IB 03/02339

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0489647	A	PL	292624 A1	08-03-1993
		PT	99671 A ,B	30-10-1992
		SI	9111886 A ,B	28-02-1998
		SK	280642 B6	16-05-2000
		RU	2099353 C1	20-12-1997
		US	5550116 A	27-08-1996
		ZA	9109518 A	26-08-1992